Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2011

PHOSPHODIESTERASE-5 INHIBITION: A NOVEL STRATEGY TO
IMPROVE STEM CELL THERAPY IN THE HEART
Nicholas Hoke
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Biochemistry, Biophysics, and Structural Biology Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/182

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

© Nicholas Nelson Hoke, 2011
All Rights Reserved

PHOSPHODIESTERASE-5 INHIBITION: A NOVEL STRATEGY TO IMPROVE STEM
CELL THERAPY IN THE HEART
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
by

NICHOLAS N. HOKE
B.S., Virginia Polytechnic Institute and State University, 2005

Director: DR. RAKESH C. KUKREJA, PH.D.
PROFESSOR
SCHOOL OF MEDICINE

Virginia Commonwealth University
Richmond, Virginia
May 2011

ii

Acknowledgement
I would like to express my sincere gratitude to Dr. Rakesh Kukreja for his mentorship, guidance,
and support throughout my pursuit of this advanced degree. His willingness to allow me to
pursue the degree of Doctor of Philosophy in Biochemistry under his world renowned expertise
in the field was vital to my completion. Futhermore, I would like to express my deepest thanks to
Dr. Salloum, Dr. Das, Dr. Xi, Dr. Ockaili, Dave Durrant and all other members of the Kukreja
Lab past and present that I worked with for countless hours throughout the years. Their time
spent to help teach or assist with numerous experimental procedures/protocols, scientific
concepts/strategies, and sharing of their knowledge in the field was pivotal to the success of this
project.

My appreciation of their effort will never be forgotten nor will their friendship. In

particular, Dr. Salloum who imparted all his wisdom, expertise, support both personally and
professionally which helped to mold me to become a better scientist. His tireless efforts with the
animal occlusion models and scientific planning were essential for the development of this
project. I would also like to thank the members of my committee: Dr. Holt; Dr. Ratz; Dr. Rao;
and Dr. Diegelmann for their support and assistance while giving valuable intellectual critiques
or suggestions to further improve and ensure completion of this project resulting in attainment of
my degree. I would also like to express my appreciation for their time and kind patience in
addressing any questions or concerns I faced while conducting my research. Furthermore,
without the love and support of my entire family and friends this goal could never been achieved.

iii

Table of Contents
Page
Acknowledgements ......................................................................................................................... ii
List of Tables ...................................................................................................................................v
List of Figures ................................................................................................................................ vi
Chapter
1

Introduction ....................................................................................................................1
Characterization of Adipose Tissue-Derived Stem Cells ..........................................4
Differentiation Capacity ............................................................................................7
Potential for Myocardial Regeneration ...................................................................10
Mechanisms of Action.............................................................................................12
Preconditioning of Stem Cells .................................................................................17
PDE-5 Inhibitors......................................................................................................18
Nitric Oxide/cGMP/Protein Kinase G Signaling ....................................................20
Rationale for Study ..................................................................................................23

2

PDE-5 Inhibition Protects Adipose-Tissue Derived Stems Cells Against Ischemia
Through a PKG-dependent Mechanism ..................................................................24
Materials and Methods ............................................................................................27
Results .....................................................................................................................42
Discussion ...............................................................................................................61

iv

3

Preconditioning by Phosphodiesterase-5 Inhibition Improves Therapeutic Efficacy of
Adipose Derived Stem Cells Following Myocardial Infarction .............................66
Materials and Methods ............................................................................................70
Results .....................................................................................................................76
Discussion ...............................................................................................................86

4

Conclusions and Future Directions ..............................................................................92

References ......................................................................................................................................95

v

List of Tables
Page
Table 1: Surface Characterization of Isolated ASCs. ....................................................................43

vi

List of Figures
Page
Chapter 1:
Figure 1: Proposed mechanism(s) of ASC transplantation in mediating cardioprotection .......... 16
Chapter 2:
Figure 2: Experimental Protocol ....................................................................................................41
Figure 3: Expression of transcription factors and differentiation of ASCs ...................................44
Figure 4: PDE-5 Immunofluoresence in ASCs ..............................................................................46
Figure 5: Expression of PDE-5 in ASCs........................................................................................47
Figure 6: Effect of PDE-5 Inhibition on Protection of ASCs from necrosis .................................48
Figure 7: Effect of PDE-5 Inhibition on Protection of ASCs from apoptosis ...............................49
Figure 8: PDE-5 Inhibition increases cGMP and PKG Activity ..................................................51
Figure 9: Sildenafil protects ASCs against necrosis through PKG dependent mechanism ...........52
Figure 10: Sildenafil protects ASCs against apoptosis through PKG............................................53
Figure 11: PDE-5 Inhibition increases the release of growth factors following
ischemia/reoxygenation in ASCs ...................................................................................................55
Figure 12: Increased NOx levels following sildenafil treatment ...................................................57
Figure 13: Conditioned media attenuates necrosis of cardiomyocytes following
ischemia/reoxygenation .................................................................................................................59
Figure 14: Conditioned media attenuates apoptosis of cardiomyocytes following
ischemia/reoxygenation .................................................................................................................60

vii

Chapter 3:
Figure 15: Experimental Protocol ..................................................................................................72
Figure 16: Tracking of PKH26 labeled ASCs following myocardial infarction ...........................77
Figure 17: Transplantation of preconditioned ASCs improves cardiac function and remodeling
following myocardial infarction ....................................................................................................80
Figure 18: Preconditioned ASCs reduces myocardial fibrosis following myocardial infarction ..81
Figure 19: Preconditioned ASCs reduces apoptosis following myocardial infarction ..................82
Figure 20: Preconditioned ASCs increases vascular density following myocardial infarction .....84
Figure 21: Transplantation of preconditioned ASCs enhances release of growth factors following
myocardial infarction .....................................................................................................................85

Abstract

PHOSPHODIESTERASE-5 INHIBITION: A NOVEL STRATEGY TO IMPROVE STEM
CELL THERAPY IN THE HEART

By Nicholas N. Hoke, Ph.D.
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Virginia Commonwealth University, 2011

Major Director: Dr. Rakesh Kukreja, Ph.D
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Several studies have shown cellular replacement therapy as a treatment strategy of myocardial
infarction but results have been limited. Therefore, enhancing the therapeutic potential of stem
cells injected into ischemic microenvironments by novel preconditioning (PC) techniques is
critical for improving cellular therapy.

Recent studies have shown that inhibition of

phosphodiesterase-5 (PDE-5) is a powerful strategy to precondition the heart and
cardiomyocytes against ischemia/reperfusion injury. We therefore tested the hypothesis that
inhibition of PDE-5 with sildenafil (Viagra®) or selective knockdown with a silencing vector in
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adipose derived stem cells (ASCs) would improve their survival after ischemia/reoxygenation in
vitro and enhance cardiac function following myocardial implantation in vivo.
ASCs were treated with sildenafil or infected with PDE-5 silencing vector shRNA
(shRNAPDE-5). The cells were subjected to simulated ischemia (SI) and reoxygenation (RO).
Both sildenafil and shRNAPDE-5 significantly reduced cell injury, as shown by improved
viability, decreased lactate dehydrogenase, and apoptosis. The preconditioned ASCs also
demonstrated an increase in the release of growth factors including VEGF, b-FGF, and IGF. The
protective effect against SI/RO injury was abolished by inhibition of protein kinase G (PKG)
using both a pharmacological inhibitor and selective knockdown with shRNAPKG1α suggesting a
PKG-mediated mechanism. To show the effect of preconditioned ASCs in vivo, adult male CD-1
mice underwent myocardial infarction (MI) by occlusion of the left descending coronary artery,
followed by direct injection of PBS (control), non-preconditioned ASCs, or preconditioned
ASCs (4x105) ASCs into the left ventricle (LV). Preconditioned ASC-treated hearts showed
consistently superior cardiac function by all measures as compared with PBS and nonpreconditioned ASCs after 4 weeks of treatment.

Post-mortem histological analysis

demonstrated that preconditioned ASC-treated mice had significantly reduced fibrosis, increased
vascular density and reduced resident myocyte apoptosis as compared to mice receiving nonpreconditioned ASCs or PBS. VEGF, b-FGF, and Ang-1 were also significantly elevated 4
weeks after cell therapy with preconditioned ASCs.

Our data suggests that genetic or

pharmacological inhibition of PDE-5 is a powerful new approach to improve stem cell therapy
following myocardial infarction.

CHAPTER 1
INTRODUCTION

Cardiovascular disease remains a leading cause of morbidity and mortality in the United
States, affecting approximately 5–6 million Americans, particularly those of age 65 and older. A
continually aging population is expected to result in an increased number of people afflicted with
heart-related conditions, requiring costly long-term medical management with an unpredictable
effect on quality of life. The most common cardiovascular disease in the United States is
coronary heart disease, which often appears as an acute myocardial infarction (MI) caused by the
sudden occlusion of the coronary artery. In 2010, an estimated 785,000 Americans had a new
coronary attack, and about 470,000 had a recurrent attack.

About every 25 seconds, an

American will have a coronary event, and about one every minute will die from one (1). Despite
advances in treatment of MI that result in reduced mortality, congestive heart failure secondary
to infarction continues to be a major complication. MI is projected to remain one of leading
causes of death for years to come; therefore, there is a continuous demand for safe and efficient
preventive or therapeutic strategies (2).

Etiologies of heart failure development are numerous and involve complex molecular
mechanisms, not entirely understood. However, recent advances have expanded our knowledge
and understanding of the cellular and molecular mechanisms involved in the development of
1
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heart failure. The occlusion of an artery creates an ischemic microenvironment by depriving
areas of the myocardium of blood, oxygen and nutrients, which if maintained for any significant
amount of time will trigger a cascade changing the cellular metabolism and function within the
tissue primarily from decreased amounts of energy produced in the form of ATP. The lack of
sufficient amounts of ATP can eventually lead to severe cellular and tissue damage such as
myocyte hypertrophy, myocyte death, and disruption of matrix metalloproteinase balance (3).
The degree of injury is dependent on the period for which the myocardium is subjected to
ischemia, with a longer duration leading to a decreased chance of recovery (4). Prolonged bouts
of ischemia leads to a variety of pathophysiological states such as a decrease in force generation,
contracture, arrhythmias, calcium overload, a decrease in pH of the tissue and eventual cell death
(5). The loss of contracting myocardium and a resulting increase in the workload on the viable
myocardium causes cardiac overload due to increased energy usage and supply-demand
imbalance (ATP depletion), which lead to cellular necrosis and apoptosis. This subsequently
promotes acute and chronic transformation of both the necrotic infarct zone and the nonnecrotic,
peri-infarct tissue, leading to global alterations that have collectively been termed ―ventricular
remodeling‖ (6, 7). Progressive cardiac hypertrophy that occurs in response to MI is known to
increase the risk of heart failure, although it is believed to be compensatory at the initial stages of
remodeling (8). Because of the loss of cardiomyocytes during an MI, the heart, as a result, is
unable to maintain a cardiac output appropriate for the requirements of the body.
The main factor leading to the progression of heart failure is the irreversible loss of
cardiomyocytes due to necrosis and apoptosis. To overcome myocyte loss and the heart’s limited
self-regeneration capacity, mesenchymal stem cell-based therapies are becoming increasingly
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recognized for their potential to repair the damaged myocardium post injury. Mesenchymal stem
cells are characterized for their self-renewing capacity and ability to undergo multi-lineage
differentiation. However, the use of mesenchymal stem cells for the purpose of regenerative
medicine should adhere to the following set of criteria: (i) available in abundant quantities; (ii)
collected and harvested by a minimally invasive procedure; (iii) differentiated along multiple cell
lineage pathways in a reproducible manner; (iv) can be safely and effectively transplanted to
either an autologous or allogeneic host (9).
Typically, mesenchymal stem cells are isolated from either bone marrow or adipose
tissue. Adipose tissue is an attractive source of mesenchymal stem cells for researchers and
clinicians due to the simple surgical procedure, the abundance of subcutaneous adipose tissue,
and the easy enzyme-based isolation procedures (10, 11). Adipose tissue-derived stem cells
(ASCs) have the ability to differentiate into multiple lineages of tissues, such as skeletal muscle,
bone, and fat, using specific culturing conditions containing hormones or growth factors (12-14).
Interestingly, ASCs have been shown to differentiate into spontaneous contractile myocytes (15).
Transplanted stem cells function through paracrine mechanisms to promote endogenous repair of
cardiac tissue (16-18). Moreover, differentiation of ASCs into endothelial cells has been shown
to have a strong regenerative angiogenic potential because of their ability to secrete angiogenic
and pro-survival paracrine factors (19, 20). Due to their multi-lineage differentiation potential,
ASCs are becoming a widely studied alternative to bone marrow-derived stem cells (BMSCs) for
therapeutic treatment of cardiac diseases.

4
Characterization of Adipose Tissue-Derived Stem Cells
Numerous experiments have documented the benefits of BMSCs for treating myocardial
infarction (21, 22). Yet, only in the past few years have groups started to study the benefits of
cells obtained from adipose tissue for treating heart disease. Interestingly, there are several
advantages of using adipose tissue versus bone marrow-derived cells. It is known that ASCs,
along with BMSCs, can be maintained in vitro for extended periods of time with a stable
population doubling time and low senescence levels, thus implying that there is no deterioration
in their proliferation rate (23). Multipotent stem cells from adipose tissue can be harvested from
patients by a simple surgical procedure that is less expensive and minimally invasive when
compared to obtaining cells from bone marrow. In fact, a greater frequency and yield of
multipotent stem cells from adipose tissue was reported when compared to bone marrow
isolations, approximately 5 x 105 cells versus 1 x 105, respectively (24). Neither the type of
surgical procedure nor the anatomical site of the adipose tissue affects the total number of viable
cells that can be obtained in the stroma vascular fraction (25). Furthermore, it has been shown
that ASCs possess a higher stem cell proliferation rate than BMSCs (24). Moreover, ASCs can
be held in culture for up to 1 month without passage while maintaining their proliferation and
differentiation potential, thus minimizing time and expenses of tissue culture maintenance. The
high yield of isolation, proliferation rate, and maintenance of differentiation potential suggests
that it is possible to obtain an autologous line of ASCs from patients undergoing elective
liposuction. Cells can also be cryogenically frozen for storage or transplanted either immediately
or after expansion in culture if needed for treatment of cardiac injury.
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The frequency and yield of ASCs and BMSCs cellular preparations are different, but they
share similar biology. It is imperative to determine the gene and protein expression profile of
ASCs to improve culturing conditions, lineage-specific differentiation, and enrichment of the
stem cell population prior to transplantation. Using fluorescence-activated cell sorting analysis,
the surface immunophenotype of ASCs was determined to resemble the phenotypes of BMSCs,
stromal cells, or skeletal muscle-derived cells (25-27). Previously reported immunophenotypes
of human ASCs and human BMSCs show them to be approximately 90% identical (28). Both
cell populations display similar mitogen-activated protein kinase (MAPK) phosphorylation in
response to tumor necrosis factor, adiponectin and leptin secretion, and lipolytic response to
adrenergic agents (13). Unfortunately, studies comparing the direct gene and protein expression
profile of ASCs and BMSCs are extremely rare. However, an important comparative micro-array
analysis of mesenchymal stem cells obtained from bone marrow, adipose tissue, and umbilical
cord clearly showed that no significant differences in morphology, immune phenotype, and
differentiation capacity were apparent between the groups (29). When compared to fibroblasts,
25 genes overlapped and were up-regulated in all cellular preparations (29). No phenotypic
differences could be determined comparing 22 surface antigens. Interestingly, hundreds of
expressed sequence tags that were differentially expressed between groups. There is some
controversy in the literature regarding the expression of the widely used marker of hematopoietic
stem cells, CD34, in ASCs (30-32). Data suggest that CD34 is absent in cultured ASCs but, by
contrast, higher levels of expression especially early in passage or lower subculture number have
been documented (32). The Stro-1 antigen, a typical BMSC surface antigen, has also been
reported to have controversial expression levels as it has been described to be absent and present
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in human ASCs (13, 33). The conflicting data might be due to the differences in either the
epitope recognized, the duration in culture, hematopoietic cell contamination, or the detection
methods, typically flow cytometry or immunohistochemistry. While both cell types share
numerous surface markers, there are some differences in protein expression between the groups
as seen when comparing ASCs and BMSCs taken from the same individual. BMSCs express the
marker CD106 while ASCs do not, but conversely ASCs express CD49d unlike bone marrow
cells (33).
The expression of important transcription factors in cultured ASCs is still present even
after 30 passages. The mRNA expression of Nanog, Oct-4, and Sox-2 was determined at
passage 30 with the expression levels of all genes being significantly lower than passage 4, yet
still detectable (24). These factors have been shown to play an important role in differentiation
of ASCs (24). Furthermore, gene expression is also affected by the time spent in culture between
passages. Culturing of cells every 14 days instead of the typical 5 days resulted in increased
expression of the stem cell-related genes thus suggesting that these cells might have a stronger
differentiation potential. Therefore, the ideal cells for therapeutic transplantation would be of a
low passage with a longer time spent in between passages.
It is important for transplanted cells not to induce an immune response from the host.
Like cells isolated from bone marrow, ASCs do not provoke in vitro alloreactivity of
incompatible lymphocytes, and they suppress mixed lymphocyte reaction and lymphocyte
proliferative response to mitogens in a dose and time dependent manner (34). This is most likely
due to the fact that less than 1% of ASCs express the HLA-DR protein, which is known to
mediate the rejection of transplanted tissue in the graft-versus-host immune response (35).
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Moreover, Rodiguez et al (35) demonstrated that adipose derived cells are immunopriviledged in
vitro and in vivo being relatively resistant to rejection after transplantation. These findings
support the idea that ASCs share immunosuppressive properties with BMSCs and therefore
might represent an alternative cellular source suitable for allogenic transplantation procedures
lacking the risk of tissue rejection.

Differentiation Capacity
In order for ASC transplantation to function properly and repair the damaged
myocardium, ASCs must have the capability to differentiate into cardiac cells thus being able to
repopulate cellular loss after infarction due to ischemia. Fortunately, differentiation of ASCs
into cells that phenotypically resemble myocytes has been detailed in several in vitro
experiments (36-38). Lineage specific differentiation of stem cells can be controlled by chemical
treatment, co-incubation with other cells, or adding growth factors to the culture medium. It has
been demonstrated that treatment with the commonly used DNA demethylating agent, 5azacytadine (9 μmol/L for 24 hours), results in differentiation of ASCs isolated from New
Zealand White rabbits into myocytes after 3 weeks in culture.

The differentiated cells were

multinucleated, began to beat spontaneously in culture and positively expressed myosin heavy
chain, α-actinin, and Troponin-I (39).
Besides chemical treatment, addition of growth factors to the culture medium will also
influence the differentiation pathway. It has been documented that medium supplemented with
interlueukin-3,-6, and stem cell factor induces differentiation of ASCs taken from male
C57Bl/6N mice into myocytes that also have pacemaker activity (15). After 24 days in culture,
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cells were beating in unison independently of 5-azacytidine treatment and clones expressed
several cardiac-specific mRNA such as GATA-4, Nkx2.5, ventricular and atrial myosin light
chains. Clones were also positive for the cardiac markers: myosin-enhancing factor 2C, αactinin, myosin heavy chain and connexin 43, while being negative for skeletal muscle markers.
Structural analysis by electron microscopy revealed multinuclear cells with morphology
consistent with cardiac myocytes. Cellular electrical activity was recorded on cells in a current
clamp and revealed an action potential characteristic to cardiac pacemaker cells.

The

differentiated cells were also capable of responding to both adrenergic and cholinergic agonists.
As expected for myocyte-like cells, isoproterenol, a β-agonist, induced a dose-dependent
increase of the spontaneous contraction rate while propranolol, a nonselective β-adrenergic
antagonist, reversed the effects.

In contrast, the nonselective acetylcholine agonist,

carbamylcholine stopped the spontaneous contractions. Furthermore, reversibly permeabilized
human ASCs co-incubated with nuclear and cytoplasmic extracts from neonatal rat myocytes
resulted in differentiation into binucleated striated spontaneously beating myocytes (39).
Finally, it has been reported by Song et al (41), using standard culture conditions without any
addition of growth factors or cytokines, that ASCs isolated from humans can spontaneously
differentiate into myocytes after 12 days in culture. Vascular endothelial growth factor (VEGF)
was identified as being critical for cardiomyogenesis (41). In fact, significant amounts of VEGF
were found in the conditioned medium which is known to significantly enhance MHC-α, cTN-I,
and Nkx2.5 expression in differentiated embryonic stem cells suggesting that VEGF is partly
responsible for the differentiation into cardiac cells via a paracrine mechanism. It has been
clearly demonstrated that ASCs will differentiate into cardiac myocytes in vitro, but a limited
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number of studies have detailed differentiation in an in vivo animal model of myocardial
infarction. Injection of ASCs taken from β-galactosidase transgene expressing Rosa26 mice into
B61295 mice immediately after permanent occlusion resulted in β-galactosidase positive cells
expressing the cardiac specific genes, myosin heavy chain, Nkx2.5, and Tropinin I (26). Similar
results were obtained when using green fluorescent protein (GFP) labeled ASCs in a rat model of
heart failure in which cells were immunohistochemically stained positive for cardiac markers 30
days post surgery (40).

Moreover, it has been reported that ASCs grown in temperature

responsive culture dishes formed a monolayer sheet due to cell-to-cell adhesions that, when
transplanted onto the ligated myocardium 4 weeks post surgery, resulted in a thickened layer of
newly generated vessels and mycoytes over the damaged area that were positive for Tropinin I
and desmin (41). These data strongly suggest that there is a great potential for ASC cellular
therapy as a treatment to repopulate the injured myocardium with differentiated cells that have a
functional pacemaker activity while phenotypically and structurally resemble myocytes.
Therapeutic enhancement of neovascularization is an important strategy needed to limit
the complications of post ischemic injury. Stem cell therapy has been shown to be promising in
neoangiogenesis in models of hind-leg ischemia (19, 42). The ability to differentiate into mature
endothelial cells, which is critical for formation of new blood vessels, gives ASCs great
angiogenic potential. Planat-Benard et al (43) observed vascular-like structure formation in
Matrigel plug using ASCs taken from mice. Cells were positive for the endothelial markers:
CD31, VE-cadherin, and von Willebrand factor.

Moreover, the cells formed branching

networks, consistent with the formation of vascular structures that lead to enhancement of the
neovascularization reaction in ischemic tissue. It has also been shown that ASCs can form
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numerous tube-like structures, and, while in the presence of erythrocytes, demonstrated the
existence of a functional vascular structure (44). Similarly, CD31 expression and differentiation
into vascular structures is enhanced by VEGF. If VEGF were added to the growth medium,
human ASCs display an endothelial phenotype (45). All these results clearly demonstrate that
there is a relationship between VEGF and lineage specific differentiation. In vivo studies also
support the potential of endothelial differentiation. Using a model of hind-limb ischemia in rats,
transplantation of ASCs improves angiogenesis and recovery of vascular blood supply (19).
Several groups have reported similar results that transplanted ASCs can integrate as fully
functional and differentiated endothelial cells (26, 46-48).

Furthermore, Zhang et al (48)

demonstrated that BrdU-labeled ASCs differentiate into myocytes and endothelial cells that
participate in vessel-like structure formation. It is clear that cellular transplantation of stem cells
derived from adipose tissue is a viable option for repairing damaged myocardium through
differentiation into myocytes and endothelial cells that become an integral part of new vascular
structures.

Potential for Myocardial Regeneration
Over the past several years, experimental findings suggest there is a therapeutic potential
for cellular replacement therapy as treatment of MI and other progressive chronic cardiac
diseases such as left ventricular (LV) remodeling and heart failure. Since cardiovascular disease
remains a worldwide problem, the development of novel effective cell-based therapies is crucial
to improve patient outcome post MI. Current treatment of MI still leaves a significant number of
patients with impaired cardiac function that leads to more severe LV dysfunction and adverse
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remodeling. Remodeling of the ventricle is a result of increased apoptosis in the ischemic zones
after infarction. While apoptosis influences remodeling, the other form of cellular death that
occurs in the heart, necrosis, provokes inflammatory reactions, neoangiogenesis, fibroblast
activation, and scar formation. To date, most of the cellular based therapies have involved the
use of myoblasts or BMSCs that often result in an improvement in LV function but have little
effect on preventing LV remodeling (22, 49, 50). Recently, studies have shown that ASCs have
become a viable alternative option to further limit remodeling and the progression to LV
dysfunction post MI (29, 47, 48, 51, 52). In a model of acute MI, rats underwent ligation of the
left anterior descending coronary artery for 45 minutes, then were allowed to reperfuse for 15
minutes before receiving an intramyocardial injection of GFP-labeled ASCs. Interestingly, 12
weeks later, there was very poor engraftment, but cell-treated animals had more capillaries and
arterioles per mm2 in the infarct border zone with a similar trend in the infarct area. The
remodeling seen in the control animals was not detected in the ASC-treated group (51).
Furthermore, a significant increase in LV ejection fraction and fractional shortening compared to
control mice at 2 weeks following permanent occlusion of the coronary artery has been reported.
The improvement in cardiac function also correlated with a significant decrease in LV endsystolic diameter (53). Interestingly, reversed wall thinning in the scar area has been seen at 30
days after permanent ligation (40). The reconstruction of thick myocardial tissue reduces the
stress on the LV wall subsequently improving cardiac function. Similar results from a direct
comparison of intracoronary injection of ASCs and BMSCs in a porcine model of MI revealed
that ASC treatment substantially improved LV perfusion, function and attenuated adverse
remodeling. The capillary vessel density was found to be greater in the ASC treatment group
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versus the group receiving BMSCs (40). This data suggest that angiogenesis may contribute to
the maintenance of cardiac function by preservation of the remaining viable myocytes and
through neovascularization, thus protecting the myocardium in the border zone that would
normally undergo apoptosis.

Mechanisms of Action
There are three proposed mechanisms through which ASCs can be used to repair and
regenerate damaged myocardium: myocyte regeneration, vasculogenesis, and paracrine actions.
Cell therapy as treatment of cardiovascular diseases was originally thought to repopulate the
myocardium, but growing evidence supports the hypothesis that paracrine mechanisms play an
essential role in repairing the damaged myocardium.

Paracrine factors are released from

endogenous cells of the heart in response to injury. These pro-survival growth factors or
cytokines mediate multiple mechanisms such as increased blood flow to ischemic tissue,
reduction in myocyte apoptosis, regulation of inflammatory response, and recruiting endogenous
stem cells to regenerate injured tissue. Additionally, administration of conditioned media from
hypoxic ASCs significantly increased endothelial cell growth and reduced endothelial cell
apoptosis, while transplantation of these cells into ischemic hind limbs led to improved
perfusion, suggesting that paracrine factors from these cells promote neovascularization (54).
Similar effects have been seen in the heart as injection of conditioned media decreased apoptosis,
fibrosis, and LV dilatation and increased myocardial thickness after infarction (48). The absence
of cells in the treatment proves that a paracrine mechanism from growth factors released in the
conditioned media plays an important beneficial role in repairing the damaged myocardium.
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Induction of neovascularization is crucial for limiting the damage in ischemic tissue; however,
studies suggest that only a small number of blood vessels contain transplanted donor cells. It is
known that angiogenesis and arteriogenesis typically involve mediators such as nitric oxide,
VEGF, basic fibroblast growth factor (b-FGF), hepatocyte growth factor (HGF), interleukin-1β
(IL-1), tumor necrosis factor-α (TNF-) and the angiopoietins. Interestingly, hypoxic
preconditioning of cells induces expression of activated Akt and endothelial nitric oxide synthase
(eNOS), while also secreting higher levels of VEGF, b-FGF, HGF, insulin-like growth factor
(IGF)-1 when compared to cells cultured under normal culture conditions. The transplantation of
the cells led to a significant increase in blood vessel density (55). The release of the angiogenic
factors augmented the vessel number without incorporation into mature vessels. Tissue levels of
VEGF and b-FGF are significantly increased in infarcted hearts that are treated with ASCs (56).
Moreover, the expression of these growth factors correlated with increased angiogenesis and
reduction in infarct size.
Besides the increase in new blood vessel formation, it is important that the paracrine
factors function to protect resident cells, particularly myocytes, from apoptosis. Transplantation
of ASCs along with their secretion of VEGF, b-FGF, IGF, and SDF-1 has been shown to
upregulate the anti-apoptotic protein, Bcl-2, which results in the decrease in myocyte apoptosis
in vitro and in vivo (57). Furthermore, intramyocardial injection of adenoviruses over-expressing
VEGF or b-FGF decreases infarct size and increases expression of Bcl-2 (21). It has been shown
that stem cells over-expressing Akt led to a decline in myocyte apoptosis in vitro and that
transplantation led to a decrease in infarct size (57, 59). The Akt over-expressing cells secreted
several paracrine factors such as VEGF, b-FGF, thymosin 4 (TB4) and HGF. HGF has been
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shown to have anti-apoptotic effects in acute MI (60). Additionally, transplantation of ASCs
over-expressing HGF into MI rat models induced myocardial angiogenesis, suppressed fibrosis
and improved cardiac function better than transplantation of ASCs alone (61). Also the G-actin
sequestering peptide, TB4, promotes survival of embryonic and postnatal cardiac myocytes, and
treatment results in enhanced myocardial survival suggesting that ASCs protect the myocardium
from apoptosis through paracrine effects (62). Myocardial injury provokes an inflammatory
response resulting in an increased expression of a variety of both pro-inflammatory and antiinflammatory cytokines.

Initially, inflammatory cytokine expression is necessary for

maintaining homeostasis in the heart after stress or injury, however, sustained upregulation of
certain cytokines leads to adverse remodeling and heart failure (63).

There is increasing

evidence that ASCs secrete cytokines that may directly act to limit deleterious, sustained
endogenous inflammation. In fact, cellular administration led to a downregulation of TNF-, IL1, and IL-6, which are involved in adverse LV remodeling (64).

Furthermore, cell

transplantation attenuated myocardial dysfunction in a rat model of acute myocarditis (65).
Also, conditioned media protected isolated adult rat cardiac myocytes from MCP-1 induced
injury, suggesting that the anti-inflammatory effects were due to paracrine factors. Data also
suggests that ASCs may directly modulate T lymphocyte function in the heart, possibly leading
to protection against their cytotoxicity or alternatively modulate their role in cardiac remodeling.
T lymphocytes co-cultured with cardiac fibroblasts led to an increase in fibroblast pro-collagen
expression, suggesting that suppression of T lymphocyte accumulation may inhibit fibrosis (66).
Therefore, alterations in the immune response by cellular therapy may serve to improve LV
function and attenuate adverse LV remodeling.
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The direct effect on fibrosis by stem cell therapy has been demonstrated. Conditioned
media significantly attenuated proliferation of cardiac fibroblasts and up-regulated elastin,
myocardin, and DNA-damage inducible transcript 3 (67). Furthermore, type I and III collagen
expression and type III collagen promoter activity were significantly down-regulated. Gene
expression analysis revealed that stem cells had several matrix-modulating factors up-regulated
such as matrix metalloproteinase-2 (MMP-2), tissue inhibitors of matrix metalloproteinases
(TIMP)-1 and TIMP-2, thrombospondin-1, and tenacin C, suggesting a direct effect on
extracellular matrix remodeling (68). A reduction in fibrosis, along with a reduction in levels of
MMP-2 and MMP-9, has been documented after injection of ASCs in models of MI (68). IL-1,
which is secreted by ASCs, has a direct anti-proliferative effect on cardiac fibroblasts (20). The
paracrine factors secreted by ASCs may play a crucial role in extracellular matrix remodeling
that contributes to improvements in LV function. Figure 1 depicts the proposed mechanism of
how ASC transplantation mediates cardioprotection through differentiation, neovascularization,
and paracrine effects on the host cells.
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Figure 1. Proposed mechanism(s) of ASC transplantation in mediating cardioprotection.
Addition of growth factors to the medium, preconditioning with hypoxia or adenoviral overexpression of Akt or HGF enhances differentiation into cardiomyocytes or endothelial cells
while also inducing a greater survival paracrine effect in host cells.
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Preconditioning of Stem Cells
Various animal studies show the potential to regenerate myocardium, improve perfusion
to the infarct area, and improve cardiac function (69-72). Phase II and III clinical studies indicate
that stem cell transplantation is feasible and may have beneficial effects on ventricular
remodeling after myocardial infarction. However, the majority of transplanted cells are readily
lost after transplantation because of the poor blood supply, ischemia/reperfusion injury, and
inflammatory factors. Disconcerting reports have shown that up to 99% of transplanted cells are
lost within the first 24 hours (73). Therefore, enhancing cell viability and reduction of apoptosis
of ASCs in an ischemic microenvironment of the infarcted heart is critical for improving the
efficiency of cell therapy. To improve the effectiveness of stem cell transplantation various
methods have been employed to increase cell survival. Recently, Zhang et al. demonstrated that
ischemic preconditioning of stem cells attenuated apoptosis induced by simulated ischemia (SI)
and re-oxygenation (RO) (74).

Subjecting cells to sublethal bouts of hypoxia prior to SI/RO

resulted in preconditioning that correlated with stabilized membrane potential, upregulation of
Bcl-2 and VEGF. Furthermore, there was an increased phosphorylation of ERK and Akt (74).
Other models have shown that the effect of ischemic preconditioning can be mimicked
pharmacologically by using phopshodiesterase-5 (PDE-5) inhibitor, sildenafil (75).

Using

mitoKATP channel opener, diazoxide, Ashraf et al. preconditioned skeletal myoblasts to promote
their survival in the infarcted heart (76). Diazoxide preconditioning of the cells significantly
induced expression of p-Akt, b-FGF, HGF, and COX-2. Treatment of cells with wortmannin
prior to preconditioning abolished the effects and significantly reduced their survival thus
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demonstrating the importance of the PI3K-Akt signaling cascade. Positive results have been
demonstrated using genetic modulation of stem cells with transgenes that overexpress angiogenic
growth factors such as Ang-1, VEGF, or Akt to improve cell survival, neovascularization, and
cardiac function by limiting the remodeling process in the scar while decreasing apoptosis of
myocytes in the peri-infarct region (77, 78). Moreover, genetically modified cells seem to
function in autocrine and paracrine manner to confer therapeutic effects. Transplantation of cells
over-expressing VEGF not only were protected from apoptosis but also reduced the apoptotic
index of host myocytes. There was also improvement in regional blood flow in the myocardium
leading to preservation of cells and myocardial structure.

Jian et al. (77) showed the

cytoprotective effects of co-overexpression of Ang-1 and Akt. Transduction with Ang-1 and Akt
genes resulted in marked survival of the transplanted cells in vivo, their differentiation into
myocytes and participation in neovascularization, which caused a reduced infarct size and
optimally preserved cardiac function after MI (77).

PDE-5 Inhibitors
Phosphodiesterase type-5 (PDE-5) inhibitors are a class of vasoactive drugs that have
been extensively used for treatment of heart failure, pulmonary hypertension, and coronary artery
disease besides their use for the treatment of erectile dysfunction (79-82). The mechanism of
action involves active inhibition of the PDE-5 enzyme resulting increase in cyclic guanosine
monophosphate (cGMP) and smooth muscle relaxation in the penis. There are 11 families of
PDEs that have been identified in mammalian tissues (83, 84). The PDEs vary in their substrate
specificity for cyclic adenosine monophosphate (cAMP) and cGMP: PDE-5, PDE-6 and PDE-9
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are specific for cGMP; PDE-4, PDE-7 and PDE-8 are specific for cAMP; and PDE-1, PDE-2,
PDE-3, PDE-10 and PDE-11 have mixed specificity for cAMP/cGMP (85). PDE-5 inhibitors
compete with the substrate cGMP for binding to the protein at the catalytic site. Although cGMP
binding to the catalytic site stimulates cyclic-nucleotide binding to the allosteric sites, inhibitors
do not elicit the same property, and Ser92 phosphorylation has no effect on inhibitor binding.
PDE-5 is the primary enzyme with cGMP-hydrolyzing activity in human corpus cavernosal
tissue (85). PDE-5 inhibitors have been studied extensively for their role in regulation of
vascular tone and blood-flow balance during erection. During erection, nitric oxide (NO) is
released from non-cholinergic, non-adrenergic neurons and from endothelial cells. NO diffuses
into cells, where it activates soluble guanylyl cyclase, the enzyme that converts GTP to cGMP,
which then stimulates protein kinase G (PKG) and initiates a protein phosphorylation cascade.
This results in a decrease in intracellular levels of Ca2+ ions, leading to dilation of the arteries
that bring blood to the penis and compression of the corpus cavernosum. A PDE-5 inhibitor
inhibits enzymatic hydrolysis of cGMP by binding to the cGMP-catalytic sites thereby allowing
the accumulation of cGMP in the erectile tissue (85).
PDEs are found in all tissues besides the human corpus cavernosal tissue, but the
distribution of the PDEs varies among different tissues and cell types (86). PDE-5A has a wide
distribution in the body tissues and cells where it exists in three isoforms; PDE-5A1, PDE-5A2,
PDE-5A3 that only differ in their N-terminal sequence (87). Immuohistochemical studies have
demonstrated the presence of PDE-5A isoforms in vascular and bronchial smooth muscle and in
platelets. It is not clear whether PDE-5A is present in the human myocytes. However, a recent
study by Senzaki et al. (88) provided evidence for PDE-5A expression in canine cardiomyocytes
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and our laboratory reported expression in mouse heart (75). Despite these interesting
observations, little is known about the distribution of PDE-5A in stem and progenitor cells.
However, recently it has been reported that cultured bone marrow derived mesenchymal stem
cells predominantly express PDE-5A (89).
The cytoprotective effects of PDE-5 inhibitors have been observed in heart cells, neurons
and glia, and epithelial cells. The precise mechanisms for these protective effects are quite
complex. We have demonstrated that sildenafil (Viagra®) and other PDE-5 inhibitors induce
powerful protective effect against ischemia/reperfusion injury in the rabbit and mouse heart (9094), DOX-induced cardiomyopathy (95, 96) and myocardial infarction-induced heart failure in
mice (97). Furthermore, we showed that PDE-5 inhibition protects isolated adult cardiomyocytes
from SI/RO. The cardioprotective effect is attributed to limiting apoptosis and necrosis through
enhanced expression of nitric oxide synthases (NOS), particularly, eNOS/iNOS, activation of
protein kinase C and PKG, phosphorylation of ERK1/2, PKG-dependent phosphorylation of
GSK-3β, NO-dependent upregulation of Bcl-2/Bax and opening of the mitochondrial KATP
channels (75, 91-93, 97, 98).

Nitric Oxide/cGMP/Protein Kinase G Signaling
Nitric Oxide (NO) is well recognized as a key mediator in cell signaling processes. It is
produced from L-arginine through chemical reaction catalyzed by at least three major isoforms
of

nitric oxide synthase, i.e. neuronal (nNOS), inducible (iNOS), endothelial (eNOS).

NO/cGMP/PKG signaling is a widely studied pathway in many tissues and cells, and reduced
production and function of NO has been shown to participate in a number of disorders such as
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cardiovascular, pulmonary, endothelial, renal, and hepatic diseases and erectile dysfunction. NO
is produced and released from many cell types in the body where it acts as a paracrine signal in a
number of systems, including the vasculature. NO at nanomolar levels binds tightly to a
prosthetic heme on the β-subunit of NO-GC, also known as the soluble guanylyl cyclase, and
causes activation of the enzyme (99, 100). Activation of NO-GC increases conversion of GTP to
cGMP, resulting in elevation of cGMP, which initiates the cGMP-signaling pathway and
subsequent physiological changes (101). NO-induced elevation of cGMP regulates numerous
physiological processes including: relaxation of vascular smooth muscle, inhibition of platelet
aggregation, inhibition of cytokine production, blunting of cardiac hypertrophy, and protection
against myocardial ischemia/reperfusion injury (102-104). At the cellular level NO and cGMP
regulate important processes such as growth, survival, differentiation, proliferation, and
migration. These effects are largely mediated through activation of cGMP dependent protein
kinase I, PKG. (105-108). cGMP-gated channels, PDEs and PKGII are also important targets for
cGMP actions.
PKG is a serine/threonine protein kinase and is one of the major intracellular receptors
for cGMP. PKG is present in high concentrations in smooth muscle, platelets, cerebellum,
hippocampus, dorsal root ganglia, neuromuscular end plate, and the kidney vasculature (109).
PKGI isozymes (PKGIα and PKGIβ) are products of alternative splicing and differ only in the Nterminal amino acids (110, 111). PKG Iα is more sensitive to activation by cGMP. The activation
of PKG phosphorylates many intracellular proteins and regulates important physiological
functions such as relaxation of vascular smooth muscle, inhibition of cell differentiation and
proliferation, and inhibition of platelet aggregation and apoptosis (109, 112). PKG also plays an
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important role in the cardiovascular system.

Recently, we reported that sildenafil-induced

protection is dependent upon activation of PKG in adult mouse heart and cardiomyocytes (113).
This notion is based on the fact that PKG inhibitors and selective knockdown of PKG by
adenoviral vector containing short-hairpin RNA of PKG abolished the antinecrotic and
antiapoptotic effect of sildenafil in cardiomyocytes, and PKG inhibition also abrogated the
infarct size reduction by sildenafil in isolated mouse hearts. Furthermore, our labroratory also
has shown the effect of PKG Iα overexpression in protecting cardiomyocytes from SI/RO
induced necrosis and apoptosis (114).
Although research on stem cells has increased dramatically in recent years, there are very
few studies on the role of the NO/cGMP/PKG pathway in stem cells (115- 121). It has been
reported that the NO/cGMP/PKG signaling pathway has been proposed to promote stem cell-like
characteristics in glioma cells in the tumor perivascular niche of medulloglioma (118).
Interestingly, enhanced endogenous NO generation has been shown to positively regulate
proliferation of neural progenitor cells through activation of cGMP/PKG signaling pathway
(119).

Recent studies have suggested the role cGMP-mediated NO signaling plays in the

differentiation of embroyonic stem cells into myocardial cells (120, 121).

Furthermore,

expressions of mRNA and protein levels of the three NOSs and sGC, along with expression of
PKG have been shown to increase during differentiation (116). However, the role of
NO/cGMP/PKG signaling in protection of ASCs against ischemia has not been investigated.
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Rationale for Study:
The present study, a series of novel investigations designed to examine the feasibility of
effect of PDE-5 inhibition as a strategy to precondition human ASCs for improving their efficacy
in vivo after cardiac transplantation.

The rationale for this approach was the established

powerful preconditioning-like effect of PDE-5 inhibitors in cardiomyocytes (75, 98, 114) and
against ischemia/reperfusion injury in heart (92-94) previously established by our laboratory.
The purpose of the following study is to investigate the effect of PDE-5 inhibition of ASCs for
transplantation to attenuate adverse cardiac remodeling and preserve of cardiac function in a
chronic model of MI. Furthermore, we wanted to attain a better understanding of the signaling
pathways involved, which ultimately lead to enhancement of stem cell therapy.
Accordingly, the main aims of the present study were:
Aim #1)

to investigate whether PDE-5 inhibition could confer cytoprotection of ASCs
against SI/RO injury in vitro;

Aim #2)

to demonstrate the role of cGMP-dependent PKG signaling in protection of
ASCs;

Aim #3)

to show that in vivo transplantation of ASCs after ex vivo PDE-5 inhibition
improve LV function following myocardial infarction;

Aim #4)

to examine the possible role of paracrine mechanism in enhancing the
cytoprotective effects of PDE-5 inhibition.

CHAPTER 2
PDE-5 Inhibition Protects Adipose-Tissue Derived Stems Cells Against Ischemia Through
a PKG-dependent Mechanism

ABSTRACT
Several studies have implicated cellular replacement therapy as a treatment strategy for
myocardial infarction, although the results have been limited.

Therefore, enhancing the

therapeutic potential of stem cells injected into ischemic microenvironments by novel
preconditioning strategies is critical for improving cellular therapy. We tested the hypothesis
that inhibition of PDE-5 with sildenafil (Viagra®) or selective knockdown with a silencing
vector in adipose derived stem cells (ASCs) would improve their survival after simulated
ischemia/reoxygenation (SI/RO). ASCs were treated with sildenafil or infected with a PDE-5
silencing vector shRNA (shRNAPDE-5) and subjected to SI/RO. Both sildenafil and shRNAPDE-5
significantly reduced cell injury with improved viability, decreased lactate dehydrogenase release
and reduced apoptosis. The preconditioned ASCs demonstrated an increase in the release of
nitric oxide metabolites and growth factors including VEGF, b-FGF, and IGF into conditioned
medium in which treatment protected adult cardiomyocytes from SI/RO. The cytoprotective
effect seen in ASCs against SI/RO injury was abolished by inhibition of protein kinase G (PKG)
with a pharmacological inhibitor and selective knockdown with shRNAPKG. Our data shows that
in vitro inhibition of PDE-5 using either genetic of pharmacological approaches can improve
stem cell therapy following myocardial infarction.
24
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Introduction
The main factor leading to the progression of heart failure is the irreversible loss of
cardiomyocytes due to necrosis and apoptosis following ischemic injury. To overcome myocyte
loss and the heart’s limited self-regeneration capacity, recent research has focused on
transplantation of stem cells to differentiate and replenish the loss of myocytes. Various animal
studies have shown the potential to regenerate myocardium, improve perfusion to the infarct
area, and improve cardiac function (69-72). Although cardiac performance by cell-based therapy
has improved, unsatisfactory cell retention and transplant survival still plague this technique.
The available transplantation strategies achieve modest engraftment of donor stem cells in the
infarcted myocardium, primarily due to the rapid and massive loss of donor stem cells (122,
123). Several factors influence the accelerated cell death in the infarcted myocardium, including
the ischemic and cytokine-rich microenvironment, mechanical injury, maladaptation, and the
origin and quality of the donor cell preparation (124). Therefore, strategies targeted toward
enhancing stem cell survival in the ischemic microenvironment are of paramount importance for
improving cardiac regeneration. Previous studies have shown that treatment of bone marrow
stem cells (BMSCs) with hypoxia improved survival post engraftment in the infarcted heart
(125), increased proliferation rates and differentiation, and modulated their paracrine activity
(126). In addition, various pharmacological preconditioning agents including diazoxide, an
opener of mitochondrial KATP channel (77), vascular endothelial growth factor 2 (127), and IGF1 (128) have been shown to promote myogenic response of stem cells following transplantation
in the myocardium. Nevertheless, progressive strategies to improve the regenerative potential of
stem cells are critical for their utility.
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In the present study, we tested the hypothesis whether PDE-5 inhibition could improve
the survival of adipose derived stem cells (ASCs,) leading to enhanced cardiac function
following myocardial infarction in mice. Specifically we addressed the following questions: 1)
Does PDE-5 inhibition by sildenafil or genetic knock-down with a silencing vector improve
survival following simulated ischemia/reoxygenation (SI/RO) injury in vitro?; 2) What is the role
of cGMP-dependent PKG signaling pathway in protection of ASCs?; 3) What is the role of
paracrine mechanisms for enhancing cytoprotective effects of PDE-5 inhibition? Our results
show that preconditioning of ASCs enhances release of cytokines such as VEGF, b-FGF, and
IGF-1, stimulates NO metabolites, activates PKG, and increases cell viability after SI/RO, all of
which were was abolished with PKG inhibition.
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Materials and Methods
Isolation of Adipose Derived Stem Cells
Epicardial adipose tissue was harvested from voluntary patients undergoing transplant.
Adipose tissue was mechanically disrupted with a scalpel and washed twice with phosphate
buffered saline. Minced fat tissue was digested for an incubation period of 90 min at 37°C on a
shaker in 20 mL of sterile filtered PBS containing 25 mg of Collagenase type VIII (SigmaAldrich) and 5 mM calcium chloride. The digested tissue was filtered through a 100 μm nylon
mesh filter (Millipore). Filtrate was centrifuged at 800 x g for 10 min. The supernatant
containing adipocytes and debris was discarded and the pelleted cells were washed twice with 40
mL Hank’s Balanced Salt Solution (Cellgro). Freshly isolated ASCs were plated with α-MEM
containing 20% FBS, 1% L-glutamine (0.2 M, Cellgro) and 1% Penicillin (10,000 U/mL) with
Streptomycin (10 mg/mL, Cellgro). Plastic adherent cells were named human adipose tissue
derived stem cells (ASCs) and were grown in culture at 37° C in a humidified incubator at 5%
CO2 followed by daily washing for three days to remove red blood cells and non-adherent
hematopoietic cells. ASCs were then plated after 3 days for subsequent experiments at a density
of 1000 cells/cm2.

Subsequent passages were performed with a 0.25% trypsin solution

containing 0.01% EDTA for 6 minutes at 37°C.

Flow Cytometry
Cell surface antigen phenotyping was performed on ASCs that were harvested upon
reaching 90% confluency. Cells were pelleted at 500 x g for 5 minutes at 4°C. Approximately,
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1 x 106 ASCs were incubated for 1 h at 37°C with primary FITC conjugated antibodies at a
dilution of 1:1000 for CD 14, CD29, CD44, CD45, CD105 and HLA-DR2 (Invitrogen,
Molecular Probes.) Mild agitation was used every 10 min to further mix the solution and prevent
cell clumping. No antibody controls were tested for each individual antibody. Cells were
counted on a Beckman CoulterElite XL-MCL single-laser flow cytometer at a minimum of
10,000 counts. Positive results were defined as over 97% of cells expressing the surface protein
of interest.

Differentiation of ASCs
Adipogenesis was induced in ASCs using a mesenchymal stem cell adipogenesis kit
(Millipore) according to manufacturer’s instructions. In brief, ASCs were plated at a density of
60,000 cells per well in a 24- well culture dish in 1 mL of medium and incubated at 37°C in a
5% CO2 humidified incubator overnight.

Once reaching 100% confluence, medium was

aspirated and 1 mL of adipogenesis induction medium (low glucose DMEM containing 10%
FBS, 1 μM dexamethasone, 0.5 mM IBMX, insulin (10 μg/mL), 100 μM Indomethacin, and 1 %
Pen/Strep) was added. This medium change corresponds to differentiation day 1. Adipogenesis
induction medium was changed every 2-3 days for 21 days. Positive staining of Oil Red-O
indicated adipogenic phenotype.
Osteogenesis was induced in ASCs using HyClone AdvanceSTEM Osteogenic
Differentiation Kit (Thermo Scientific) according to manufacturer’s instructions. In brief, ASCs
were plated at a density of 60,000 cells per well in a 24 well culture dish with 1 mL of medium
and incubated at 37°C in a 5% CO2 humidified incubator overnight. Once reaching 100%
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confluence, medium was aspirated and 1 mL of osteogenic induction medium supplemented with
1 nM dexamethasone, 2 mM β-glycerophosphate, and 50 μM ascorbate-2-phosphate.

ASCs

were induced for 14 days and the the osteogenic medium was replaced every 2-3 days.
Osteogenic mineralization was assessed after 21 days by staining with 40 mM Alizarin red
(Sigma).

Immunocytochemistry
ASCs were cultured on sterile glass cover slips and fixed by incubation in 4%
paraformaldehyde/ PBS for 20 min and permeabilized with 1.0% Triton X-100 in PBS for 10
min. Intracellular staining patterns and distribution of Oct-4, Sox-2, Nanog, and PDE-5 proteins
were analyzed by immunostaining with incubation of respective antibodies at 4°C overnight
(1:500 dilution) followed by incubation of FITC conjugated secondary antibodies at 37°C for 1 h
(1:1000 dilution). Staining of 4’,6-diamino-2-phenylindole (DAPI; Sigma) was used to visualize
all nuclei.

Western blot analysis
Total soluble protein was extracted from ASCs with extraction buffer containing 50 mM
Tris-HCl (pH 7.5), 5 mM EDTA, 10 mM EGTA, 50 μg/ml PMSF, protease inhibitor cocktail
(10μl/ml, Sigma), 0.3% β-mercaptoethanol as described by Qiu et al. (129). Homogenate was
centrifuged at 14,000 x g for 10 min at 4 °C, and the supernatant was recovered as the total
cellular protein. Total protein (50 µg) from each sample was separated by SDS-PAGE,
transferred to a nitrocellulose membrane, and then blocked with 5% nonfat dry milk in Tris-
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buffered saline. The membrane was subsequently incubated with a primary antibody at a dilution
of 1:500 for each of the respective proteins, i.e. PDE-5A, Oct-4 (rabbit polyconal), PKG, β-actin
(goat polyclonal, Santa Cruz), SOX-2, and Nanog (mouse monoclonal, BD Biosciences). The
membrane was washed and incubated with horseradish peroxidase-conjugated secondary
antibody (1:2000 dilution, 1 h at room temperature). The membranes were developed using
enhanced chemiluminescence system (ECL Plus; Amersham Biosciences) and exposed to X-ray
film.
Preparation of shRNAs
PDE-5 gene silencing shRNA (inserted into miRNA-155 cassette) and gfp-PDE-5 fusion
protein both coupled to a CMV promoter and incorporated into adenoviral vectors were
generated by Zhang et al (130). In brief, short-hairpin RNAs were designed based on mouse
PDE5A sequence
(shRNAPDE5-1899:

5′-

FORWARD

TGCTGTTTCAGAGCAGCAAACATGCAGTTTTGGCCACTGACTGACTGCATGTTCTGC
TCTGAAA-3′

and

REVERSE

5′-

CCTGTTTCAGAGCAGAACATGCAGTCAGTCAGTGGCCAAAACTGCATGTTTGCTGCT
CTGAAAC-3′;

shRNAPDE5-2066

FORWARD

5′-

TGCTGAAATGATGGTGTTCCATGATGGTTTTGGCCACTGACTGACCATCATGGCACC
ATCATTT-3′

and

REVERSE

CCTGAAATGATGGTGCCATGATGGTCAGTCAGTGGCCAAAACCATCATGGAA-3′)

5′-
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and

inserted into pcDNA 6.2-GW/EmGFP-miR-155 vector (Invitrogen) retaining miRNA

regulatory sequences required for efficient shRNA processing. This was transferred by
recombinase cloning into pAd/CMV/V5-DEST™ vector (Invitrogen) to generate AdV-gfpshRNAPDE5A. AdV was CsCl purified and titered at 1.5–3.0 x 1010 pfu/ml. Green fluorescent
protein (gfp) enabled infection to be confirmed (AdV-gfp virus was the control), and the miRNA
construct allowed use of the CMV promotor enhancing gene knock-down.
The mouse PKGI, shRNA expression vector for PKG was constructed as described
previously (98). In brief, to knockdown the expression of PKG, we used shRNA, targeting the
mouse cDNA of PKG type I (GenBank™ accession number NM_001013833): corresponding to
bases 1593 to 1611, targeting the sequence 5′-GAACAAAGGCCATGACATT-3′, synthesized
by Dharmacon Research Inc. (Lafayette, CO). A non-targeting scrambled RNA duplex siRNA
control (NTSC, Dharmacon) containing 21-nucleotide sequences demonstrating no homology to
murine genes was also used as a control for transfection. Transient transfections of duplex
siRNAs (100 nM) were performed in H9C2 cells using siPORT™ amine (Ambion). After 48 h,
RNA was isolated by Tri-Reagent (Molecular Research Center), and RT-PCR and quantitative
real-time PCR were performed. After confirming the significant reduction of PKG expression in
H9C2 cells using this duplex siRNA targeting the mouse PKGI, shRNA expression vector for
PKG was constructed using the pSilencer™ adeno1.0-CMV system from Ambion (Adenoviral
siRNA expression Vector System). The hairpin siRNA oligonucleotide (55-mer) sequence 5′TCGAGGAACAAAGGCCATGACATTttcaagagaAATGTCATGGCCTTTGTTCAGA-3′
(mouse PKGI with sequence in capital letters and loop in lowercase italics) and its antisense with
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XhoI and SpeI were synthesized, annealed, and subcloned into the pSilencer adeno 1.0-CMV
shuttle vector. HEK293 cells were transfected with linearized shRNA vector together with
adenoviral LacZ backbone to generate a recombinant adenovirus.

Simulated Ischemia/Reoxygenation Protocol
ASCs were incubated at 37 °C and 5% CO2 for 2 h, with or without 10 µM sildenafil.
This dose was selected based on its protective effect against SI/RO injury in adult
cardiomyocytes (75). A subset of ASCs were treated with PKG inhibitor KT 5823 (2 µM) with
or without sildenafil for 2 h. Another subset of ASCs were transduced with an adenoviral vector
containing scrambled control shRNA (shRNACon ASC), PDE-5 shRNA (shRNAPDE-5 ASC), or
PKG shRNA (shRNAPKG ASC) in serum-free growth medium for 24 h. (Fig. 2). The cells were
infected with the viruses at a concentration of 1x103 particles/cell. ASCs were then subjected to
SI for 15 h by replacing the cell medium with an ―ischemia buffer‖ that contained 118 mM NaCl,
24 mM NaHCO3, 1.0 mM NaH2PO4, 2.5 mM CaCl2-2H2O, 1.2 mM MgCl2, 20 mM sodium
lactate, 16 mM KCl, 10 mM 2-deoxyglucose (pH adjusted to 6.2) as reported previously (75).
Cells were incubated in an anoxic chamber at 37°C during the entire SI period. RO was
accomplished by replacing ischemic buffer with normal cell medium under normoxic conditions.
Cell necrosis and apoptosis were assessed after 1 or 18 h of reoxygenation, respectively.

Evaluation of Cell Viability and Apoptosis
Cell viability, trypan blue exclusion assay and lactate dehydrogenase release into the
medium were used to assess cell necrosis. Cell viability assessment was performed with
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CellTiter 96® AQueous One Solution Cell Proliferation Assay Kit (Promega), per the
manufacturer’s instructions. In brief, approximately 5,000 ASCs/well were plated into a 96-well
dish and allowed to attach overnight prior to SI/RO protocol. Following completion of SI/RO,
20μl of CellTiter 96® AQueous One Solution Reagent was added into each well and incubated
for 2 h at 37°C in a 5% CO2 before recording absorbance at 490 nm using a VersaMax
microplate reader with SoftMaxPro software (Molecular Devices). CellTiter 96® AQueous One
Solution uses a MTS tetrazolium compound which is bioreduced by cells into a colored
formazan product that is soluble in tissue culture medium. The quantity of formazan product as
measured by the absorbance at 490 nm is directly proportional to the number of living cells in
culture.
ASCs were plated at a density of 2x105 cells/mL in 2-well chamber slides prior to SI/RO
protocol. Following SI/RO, 100 μL of cellular medium was collected for LDH measurements,
and enzyme activity was monitored spectrophotometrically using an LDH assay kit (Sigma).
NAD+ is reduced to NADH/H+ by LDH-catalyzed conversion of lactate to pyruvate. The
catalyst (diaphorase) transfers H/H+ from NADH/H+ to tetrazolium salt which is reduced to
formazan. An increase in the number of dead cells leads to an increase in LDH activity in the
culture medium which correlates to amount of formazan dye formed which is measured at 490
nm. Trypan blue exclusion assay was performed as follows. Following SI/RO, floating and
attached cells were collected by centrifugation and cell pellets were resuspended and mixed with
20 μl of 0.4% trypan blue (Sigma). After ∼ 5 min of equilibration, dead cells, stained by trypan
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blue, were counted using a hemocytometer. The number of dead cells was counted from five
randomly chosen fields and expressed as a percentage of the total number of cells.
Apoptosis was analyzed by the terminal dUTP nick-end labeling method (TUNEL)
staining using ApopTag® Peroxidase In Situ Apoptosis Detection Kit (Millipore) that detects
nuclear DNA fragmentation as previously reported (98). After SI and 18 h of reoxygenation,
cells were fixed by 4% formaldehyde/PBS at 4 °C for 25 min and subjected to TUNEL assay
according to the manufacturer’s protocol. In brief, cells were washed twice in PBS for 5 min
before being permeabilized with precooled ethanol:acetic acid 2:1 for 7 min at -20°C. Cells were
washed twice in PBS for 5 min before incubation 3.0% hydrogen peroxide in PBS for 5 minutes
at room temperature to quench endogenous peroxidase. Cells were washed twice and incubated
with terminal deoxynucleotidyl Transferase (TdT) enzyme for 1 h at 37°C in a humidified
chamber. After the 1 h incubation period, cells were washed 3 times in PBS prior to incubation
with anti-digoxignenin conjugate for 30 min at room temperature. Slides were developed with
Nova Red peroxidase substrate (Vector Lab), counterstained with hemotoxylin and mounted
using Permount solution (Fisher Scientific). Stained cells were examined under a Nikon Eclipse
TE 800 microscope. TdT catalyzes a template-independent addition of nucleotide triphosphates
to the 3'- OH ends of double-stranded or single-stranded DNA. The incorporated nucleotides
form an oligomer composed of digoxigenin-conjugated nucleotide and unlabeled nucleotide in a
random sequence. DNA fragments which have been labeled with the digoxigenin-nucleotide are
then allowed to bind an anti-digoxigenin antibody that is conjugated to a peroxidase reporter
molecule. The bound peroxidase antibody conjugate enzymatically generates a permanent,

35
intense, localized stain from chromogenic substrates, providing sensitive detection of apoptotic
bodies.

cGMP, cAMP and Protein Kinase G Activity
cGMP activity assay was performed using cGMP Direct Immunoassay Kit (Biovision)
which provided a direct competitive immunoassay for sensitive and quantitative determination of
cGMP as per manufacturer’s instructions. Briefly, the cell lysate is incubated with a cGMP
polyclonal antibody at room temperature for 1 h and the excess reagents are washed away. The
substrate is added and after a short incubation period, the enzyme reaction was stopped and the
yellow color intensity was measured using VersaMax microplate reader at 405nm. The intensity
of the bound yellow color is inversely proportional to the concentration of cGMP in either
standards or samples. The measured optical density is used to calculate the concentration of
cGMP. Protein concentration of lysate was measured spectrophotometrically at 595 nm. The
results are expressed as pmol/mg of protein.
Cellular levels of cAMP were measured using bioluminescent assay, cAMP-Glo
(Promega) as per manufacturer’s instructions. In brief, approximately 5,000 ASCs/well were
plated into a 96-well dish and allowed to attach overnight prior to respective treatment. Cells
were lysed with incubation of cAMP-Glo Lysis buffer for 15 minutes at room temperature prior
to addition of cAMP-Glo Detection Solution. After 20 min at room temperature, Kinase-Glo
Reagent was added, mixed for 60 s and incubated at room temperature for 10 min.
Luminescence was measured using VersaMax microplate reader. Luminescence is inversely
proportional to cAMP levels. The results are expressed as pmol/mg of protein.
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Cardiac protein kinase G activity was examined using a commercially available PKG
activity kit (Cyclex) in whole cell lysates (n = 4/group). Activity was measured according to the
manufacturer’s instructions.

In brief, total soluble protein was extracted from ASCs with

extraction buffer containing 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 10 mM EGTA, 50μg/ml
PMSF, protease inhibitor cocktail (10μl/mL), and 0.3% β-mercaptoethanol. Cell extracts (10
μL) were plated in duplicate in a 96-well plate along with 90 μL of cGMP plus Kinase Reaction
Buffer per well. The plate was covered with plate sealer, and incubated at 30°C for 30 min.
Wells were washed 5 times with Wash buffer prior to addition of 100 μL of HRP conjugated
Detection Antibody 10H11. The plate was recovered and incubated at room temperature for 60
min. The enzyme reaction was stopped and the spectrophotometric absorbance was measured at
450 nm. Results were normalized as per mg of protein.

Measurement of VEGF, b-FGF, Ang-1and IGF by ELISA
The levels of VEGF, b-FGF and IGF released from ASCs into culture medium were
directly measured by ELISA kit according to manufacturer’s instructions (R & D Systems). In
brief, conditioned medium was added to a microplate pre-coated with the respective growth
factors for a 2 h incubation period at room temperature. Basal medium was used as a control.
The plate was washed 3 times to remove any unbound substances prior to incubation with the
respective enzyme-linked polyclonal antibody conjugate. Following washing to remove any
unbound antibody-enzyme reagent, substrate solution is added to the wells and color develops in
proportion to amount bound of respective growth factor. The absorbance was measure at 450
and 570 nm.
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Measurement of Nitrate, Nitrite and NOx
ASCs were plated at a density of 2x105 cells/mL in 10 mm2 culture dishes. ASCs were
incubated at 37 °C and 5% CO2 for 2 h, with or without 10 µM sildenafil A subset of ASCs
were transduced with an adenoviral vector containing scrambled control shRNA (shRNA Con
ASC), PDE-5 shRNA (shRNAPDE-5 ASC), in serum-free growth medium for 24 h. Conditioned
medium was collected 24 h after treatment and was subsequently centrifuged using Amicon
Ultra-4 centrifugal filter devices at 7500 g in 4oC to eliminate large molecules (molecular weight
>30 kDa) from the medium. The levels of nitrate and nitrite in the conditioned medium were
measured with a SIEVERS nitric oxide analyzer (model 280NOA). The reducing agents used
were either vanadium (III) chloride (VCl3) in 1 M HCl (for nitrate) or 1% sodium iodide (NaI) in
glacial acetic acid (for nitrite). Five to six mL of a reagent plus 100 µL of 1:30 diluted antifoaming agent were loaded into the purge vessel for analysis. These reducing agents converted
nitrite and nitrate respectively to gaseous NO at 90°C, which was quantified by the analyzer.
The results are expressed in μM of nitrite, nitrate, and NOx (total levels of nitrate and nitrate).

Isolation of Adult Mouse Ventricular Cardiomyocytes
Adult male CD1 (Harlan Sprague Dawley) were used in this study. The animal
experimental protocols were approved by the Institutional Animal Care and Use committee of
Virginia Commonwealth University. The ventricular cardiomyocytes were isolated using an
enzymatic technique modified from the previously reported method (131, 132). In brief, the
animal was anesthetized with pentobarbital sodium (100 mg/kg, i.p.) and heart was quickly
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removed. Within 3 min, the aortic opening was cannulated onto a Langendorff perfusion system
o

and heart was retrogradely perfused (37 C) at a constant pressure of 55 mmHg for ~5 min with a
Ca2+ free bicarbonate-based buffer containing: 120 mM NaCl, 5.4 mM KCl, 1.2 mM MgSO 4, 1.2
mM NaH2PO4, 5.6 mM glucose, 20 mM NaHCO3, 10 mM 2,3-butanedione monoxime, and 5
mM taurine, which was continuously bubbled with 95% O2 + 5% CO2. The enzymatic digestion
was commenced by adding collagenase type II (Worthington, 0.5 mg/mL each) and protease type
XIV (0.02 mg/mL) to the perfusion buffer and continued for ~15 min. 50 μM Ca

2+

was then

added in to the enzyme solution for perfusing the heart for another 10-15 min. The digested
ventricular tissue was cut into chunks and gently aspirated with a transfer pipette for facilitating
the cell dissociation. The cell pellet was resuspended for a 3-step Ca restoration procedure (i.e.
125, 250, 500 μM Ca). The freshly isolated cardiomyocytes were then suspended in minimal
essential medium (Sigma) containing 1.2 mM Ca, 12 mM NaHCO 3, 2.5% fetal bovine serum and
1% penicillin-streptomycin. The cells were then plated onto the 35 mm2 cell culture dishes,
which were pre-coated with 20 μg/mL mouse laminin in PBS + 1% penicillin-streptomycin for 1
hour. The cardiomyocytes were cultured in the presence of 5% CO 2 for 1 hour in a humidified
incubator at 37°C, which allowed cardiomyocytes to attach to the dish surface prior to the
experimental protocol.

In Vitro Experiments with Conditioned Medium
Conditioned medium was generated as follows: 90% confluent ASCs were treated with or
without 10 µM sildenafil for 2 h prior to being subjected to 15 h SI and 1 h RO. The medium
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was then collected and used for in vitro experiments. Adult mice cardiomyocytes were obtained
from Langendorff-perfused hearts of adult CD-1 mice, as described previously. Cells were
seeded in 2-well chamber slides precoated with laminin (30 µg/ml in PBS) and left to attach for 1
h. After attachment, the α-MEM medium was replaced with serum- free α-MEM (normal
medium) or conditioned medium from either control or sildenafil-treated ASCs. The
cardiomyocytes were then subjected to 40 min SI and 1 h RO for necrosis studies and 18 h RO
for apoptosis studies.
Cardiomyocyte Viability and Apoptosis
Cell viability was assessed by trypan blue exclusion assay as reported previously (75,
98). Cardiomyocyte apoptosis was evaluated via TUNEL that detects nuclear DNA
fragmentation via a fluorescence assay as previously reported (75, 98) using the ApoAlert™
DNA Fragmentation Assay Kit (BD Biosciences) according to manufacturer’s instructions. In
brief, after SI and 18 h of reoxygenation, cardiomyocytes in two chamber slides were fixed by
4% formaldehyde/phosphate-buffered saline at 4°C for 25 min and subjected to TUNEL assay
according to the manufacturer’s protocol. The slides were then counterstained with Vectashield
mounting medium with 4’,6-diamidino-2-phenylindole (a DNA intercalating dye for visualizing
nuclei in fixed cells, Vector Laboratories). The stained cells were examined under an Olympus
IX70 fluorescence microscope. Apoptotic index (AI) was determined from counting TUNELpositive myocyte nuclei from ten separate fields per treatment and expressed as a percentage.
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Data Analysis and Statistics
Data are presented as mean ± S.E. The differences between groups were analyzed with
one way analysis of variance followed by Student-Newman-Keuls post hoc test for pair-wise
comparison. P<0.05 was considered to be statistically significant.
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Group 1-Control
Group 2-SI-RO
Group 3-SI-RO + Sildenafil (Sil) ASC
Group 4-SI-RO + Sil + KT 5823 ASC
Group 5-SI-RO + shRNACON ASC
Group 6-SI/RO + Sil shRNACON ASC
Group 7-SI/RO + Sil shRNAPKG ASC
Group 8-SI/RO + shRNAPDE-5 ASC

15 h Simulated
Ischemia
24 hours adenoviral infection
prior to sildenafil treatment
(10μM for 2 hours);
KT 5823 (2 μM) given at time of
sildenafil treatment

•cAMP Accumulation
•cGMP Accumulation
•PKG Activity

Reoxygentation

1 hour
•Trypan Blue Exclusion
•LDH release
•MTS
•Growth Factor Release
(conditioned medium collection)

18 hours
•TUNEL

Figure 2. Experimental protocol. In vitro protocol, arrows indicate time points for treatment,
performance of simulated ischemia/reoxygenation, and measurement of various parameters for
each experimental group.
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Results
Characterization of ASCs
Fluorescence activated cell sorting analysis showed that isolated ASCs expressed
common surface expression markers CD29 (immune response), CD44 (cell-cell interactions, cell
adhesion and migration), and CD105 (angiogenesis). The cells were devoid of markers such as
CD14 (monocytes), CD45 (hematopoietic cells), and Human Leukocyte Antigen receptor DR2
(HLA-DR2) (Table 1). Immunostaining showed intense nuclear and cytosolic expression of the
pluripotent stem cell transcription factors including Oct-4, Sox-2 and Nanog in the ASCs (Fig.
3A). The expression of these proteins was also confirmed by Western blot analysis. Treatment
with sildenafil did not alter their expression (Fig. 3B). To demonstrate the differentiation
capacity of ASCs in vitro, adipogenic and osteogenic lineage specific induction factors were
used in the normal culture conditions. Adipogenic and osteogenic phenotype was determined by
staining monolayers of ASCs with Oil Red-O and Alizarin Red respectively. The ASCs showed
multiple intracellular lipid filled droplets in ~30% of cells confirming adipogenic differentiation
(Fig. 3C) and calcium deposition with Alizarin Red confirming osteogenic differentiation (Fig.
3D).

43

Table 1. Surface
Characterization of
Isolated ASCs. Surface
Marker
CD29
C105
CD44
CD14
CD45
Human Leukocyte Antigen
receptor DR2 (HLA-DR2)

Positive or Negative

+
+
+
-

Involvement

immune response
angiogenesis
cell-cell interactions, cell
adhesion and migration
monocytes
hematopoietic cells
graft vs. host immune
response

Positive results were defined as over 97% of cells expressing the surface protein of interest.
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Figure 3. Expression of transcription factors and differentiation of ASCs.
(A)
Immunohistochemical staining of Alexa 488 labeled Oct-4 (left panel- green), Sox-2 (middle
panel- green), and Nanog (right panel- green) overlayed with DAPI staining of nuclei (blue). (B)
Western Blot analysis from ASC lysate show expression of stem cell transcription factors Oct-4,
Sox-2 and Nanog. Treatment with sildenafil (SIL) did not alter their expression. (C)
Adipogenesis and lipid vesicle formation was determined by Oil Red-O staining. (D)
Mineralization was detected in osteogenic-differentiated ASCs using Alizarin red staining.
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Cytoprotection by PDE-5 Inhibition
Immunostaining showed that ASCs express PDE-5, which was localized within the
cytoplasm (Fig. 4). Moreover, adenoviral infection was confirmed by the presence of GFP
expression in shRNACON and shRNAPDE-5. PDE-5 expression was also confirmed by Western
blot and real time-PCR. shRNAPDE-5 efficiently silenced PDE-5 in ASCs at gene and protein
expression levels (Figs. 4 and 5).

Adenovirally transduced or normal cultured ASCs were

treated with or without 10 µM sildenafil for 2 h. The percentage of trypan blue-positive
(necrotic) cells increased to 24.2±3.7 as compared to non-SI/RO controls (0.6±0.1) following SI
(15 h)/RO (1 h) (n=8; p<0.01). Sildenafil treatment reduced cell death as measured by MTSbased cell incorporation (Fig. 6A) and necrosis as shown by decrease in trypan blue-positive
cells to 5.7 ±1.6% (n=8; p<0.01, Fig. 5B). PDE-5 knockdown by shRNAPDE-5 conferred a similar
protective effect when compared to the scrambled shRNA CON ASCs (7.1 ±0.9 vs. 29.3 ±1.3%, p
< 0.01, n = 8; Fig. 6). Also, combination of shRNACON with sildenafil increased cell viability
and reduced necrosis (Fig. 6). Similar results were obtained when lactate dehydrogenase (LDH)
release in the medium was used as a marker of necrosis in ASCs (Fig. 6C).
After 15 h of SI and 18 h of RO, apoptotic nuclei (TUNEL-positive cells) increased from
2.0±0.5 % (in non-ischemic control group) to 18.3±2.5 % of total cells (p < 0.01, n = 8;). PDE-5
inhibition resulted in reduction of TUNEL-positive cells to 5.7± 2.1% in sildenafil-treated ASCs
and 6.4± 0.9% in shRNAPDE-5 ASCs (p < 0.01 vs. SI-RO, n = 8; Fig. 7). These results suggest
that PDE-5 inhibition in ASCs exerts a cytoprotective against ischemic injury.
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A.

PDE-5

GFP

DAPI

Merge

ASC

shRNACON
ASC

shRNAPDE-5
ASC

Figure 4. PDE-5 immunofluoresence in ASCs. Immunohistochemical staining of PDE-5 (red),
GFP (green), DAPI staining of nuclei (blue) and overlay in ASCs with shRNA PDE-5 as compared
to shRNACON ASCs and control ASCs.
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Figure 5. Expression of PDE-5 in ASCs (A) Western blot analysis showing knock-down of
PDE-5 in ASCs with shRNAPDE-5 as compared to shRNACON ASCs and control ASCs
(representative lanes from contiguous blot; n=3). (B) Real-time PCR showing reduced PDE-5
expression; (n=3).
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B.

Figure 7. Effect of PDE-5 inhibition on protection of ASCs from apoptosis. Quantitative data
showing the effect of sildenafil (SIL) or shRNAPDE-5 on apoptosis following SI-RO as
determined by TUNEL assay (A) and representative images (B); n=8).
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Effect of PDE-5 Inhibition on cGMP and PKG Activity
PDE-5 inhibition by sildenafil or shRNAPDE-5 resulted in nearly identical increase in
cGMP levels (0.9±0.01 and 0.9±0.02 pmol/mg of protein, respectively) as compared to nontreated ASCs (0.7±0.03) and shRNACON ASCs (0.7±0.03) (p<0.05, n=4). shRNACON had no
effect on cGMP formation with sildenafil treatment (Fig. 8A). Both sildenafil and shRNAPDE-5
had no effect on cAMP levels (Fig 8B).

Also, sildenafil and shRNAPDE-5 increased PKG

enzymatic activity (A450/mg protein) as compared to control ASCs (Fig. 8D).
To determine the cause and effect relationship of PKG in sildenafil-induced survival of
ASCs following SI/RO, we used shRNA knockdown of PKG and pharmacological inhibition
approach as reported previously (99). ASCs infected with shRNAPKG caused at least 60%
knock-down of PKG (Figs. 8C). Moreover, sildenafil induced PKG activity was inhibited in
shRNAPKG ASCs or by co-treatment with PKG inhibitor, KT 5823 (Fig. 8D). The protective
effect of sildenafil against necrosis and apoptosis (Figs. 6, 7) were attenuated by KT 5823 and in
shRNAPKG ASCs (Figs. 9, 10) suggesting that inhibition of PDE-5 induced protection involves a
PKG dependent pathway.
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Figure 8. PDE-5 inhibition increases cGMP and PKG activity. (A) cGMP levels in ASCs
following preconditioning with sildenafil and shRNAPDE-5 as compared to shRNACON and nontreated ASCs. (B) cAMP levels in the same groups as in A. (C) Western blot analysis showing
knockdown of PKG expression as compared to controls (D) PKG activity in ASCs following
treatment with sildenafil or shRNAPDE-5. Treatment with 2 µM KT 5823 (KT) or shRNAPKG
inhibited PKG activity; (n=4).
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Figure 9. Sildenafil protects ASCs against necrosis through PKG dependent mechanism.
Quantitative data showing cell viability as determined by MTS assay (A), cell necrosis assessed
by trypan blue exclusion assay (B), and LDH release into the medium (C); (n=8).
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B.

SI/RO + KT & Sil ASC

SI/RO + Sil shRNAPKG ASC

Figure 10. Sildenafil protects ASCs against apoptosis through PKG. Quantitative data
showing the effect of PKG inhibitor KT 5823 (KT) and shRNAPKG on apoptosis following SIRO as determined by TUNEL assay (A) and representative images (B). The PKG inhibitor KT
5823 (KT) and shRNAPKG abolished the protective effect of sildenafil against necrosis and
apoptosis; (n=8).
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PDE-5 Inhibition Enhances Release of Growth Factors
To identify potential paracrine mechanisms responsible for the therapeutic effect of
preconditioning, we examined the effect of PDE-5 inhibition in ASCs on release of growth
factors, VEGF, b-FGF, and IGF-1 in vitro. No differences in their secretion was observed
between sildenafil-treated, shRNAPDE-5 and non-treated ASCs under normal conditions.
Following SI/RO, both sildenafil and knockdown with shRNAPDE-5 increased the release of
basic-fibrolast growth factor (b-FGF) (1.7 fold), IGF-1 (1.5 fold) and VEGF (1.4 fold) as
compared to SI/RO control. Inhibition of PKG blocked the enhanced secretion of the growth
factors (Fig. 11). These data suggests that the high-level secretion of growth factors from
preconditioned ASCs may provide cardioprotective and proangiogenic effects as a result of PKG
activation.

55

55
50
45
40
35
30
25
20
15
10
5
0

*

*

*

B.

* P<0.001 vs all groups
*
*
*

50
40
30
20
10

AS
C

E5

G

sh

Si
l

sh
Si
l

C.

RN
A
A CO S C
N
sh
RN
A
A CO S C
sh
N
RN
A PD ASC

S
R N il A
A PK SC

KT

+

PD

sh
RN

A

NA

AS
C

AS
C

Si
l

AS
C

AS
C

E5

N

AS
C

CO

N

AS
C

CO

A
Si

sh
RN

ls
hR

G

AS
C

PK

NA

ls
hR

Si

KT

+

Si

Si
l

lA
SC

0

AS
C

b-FGF release (pg/mL)

* P<0.001 vs all groups

IGF release (pg/mL)

A.

* P<0.001 vs all groups
VEGF release (pg/mL)

300

*

*

*

200

100

C
AS

-5

lA
KT
SC
+
ls
Si
hR
l
NA ASC
PK
G
sh
RN
A
Si
A CO S C
ls
N
hR
NA ASC
CO
sh
N
RN
A
A PD S C
E
Si

Si

AS
C

0

Figure 11. PDE-5 inhibition increases the release of growth factors following
ischemia/reoxygenation in ASCs. PDE-5 inhibition by sildenafil or its knockdown with
silencing vector shRNAPDE-5 augmented the release of (A) b-FGF, (B) IGF, and (C) VEGF after
SI/RO which is blocked by PKG inhibitor KT 5823 (KT) and shRNA PKG. shRNACON had no
effect; (n=4).
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Effect of Sildenafil Preconditioning on Nitrate, Nitrite and NOx
The concentrations of nitrate, nitrite and NOx (nitrate + nitrite) secreted into culture
medium was examined following PDE-5 inhibition in ASCs. Sildenafil treatment of ASCs
resulted in significant increases of nitrate (26±1.7 μM) and NOx (30.5±0.8 μM) as compared to
non-treated controls (17.9±1.7 μM and 22.3±1.7 μM, respectively, p<0.05, n=3). Interestingly,
PDE-5 inhibition through a silencing vector exhibited a trend towards enhanced secretion of
nitrate and NOx as compared to non-treated ASCs; however, did not confer a similar increase as
compared to ASCs infected with scrambled control vector (Fig. 12). Furthermore, the levels of
nitrite secreted into the medium were similar in each treatment group.
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Figure 12. Increased NOx levels following sildenafil treatment. Quantitative data showing
the effect of sildenafil (SIL) or shRNAPDE-5 on levels of nitrate (A); nitrite (B); and NOx (C) in
conditioned medium; (n=3).
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Cytoprotection of Adult Mouse Cardiomyocytes with Conditioned Medium:
We further evaluated the possible paracrine effects of conditioned medium from cultured
ASCs on isolated primary adult cardiomyocytes. Our method for isolation and cell preparation
yielded at least 85% of the cardiomyocytes with rod-shaped morphology (Fig. 13 B). Initially,
the mouse cardiomyocyte standard growth medium was replaced with normal α-MEM or
conditioned medium from control or sildenafil-treated ASCs; cardiomyocytes were subsequently
subjected to SI-RO (Fig. 13 A). Necrosis was measured by trypan blue exclusion and LDH
release. The percentage of trypan blue-positive (necrotic) cardiomyocytes increased to
41.3±5.8% as compared to non-SI/RO controls (2.0±0.8%) following SI (40 min)/RO (1 h)
(p<0.01, n=4).

Treatment with conditioned medium (CM) reduced necrosis as shown by

decrease in trypan blue-positive cells. Although the cytoprotective effect was observed in the
presence of both control and sildenafil-treated ASC-CM, the greater degree of protection was
conferred by the SIL ASC-CM (24.5±2.6% vs 32.3 ±3.9%, p<0.01, n=4, Fig. 13 C). Similar
results were obtained by measurement of LDH release in the medium (Fig. 13 D). Furthermore,
the relative number of apoptotic cardiomyocytes following 18 h of RO was measured by TUNEL
analysis. In the presence of SIL ASC-CM, the number of apoptotic nuclei was reduced to
11.5±2.9% as compared with that of normal medium (26.3±4.2%) or the control ASC-CM
(18.5±2.1%), respectively (Fig. 14). Thus, these results indicate that a paracrine cytoprotective
mechanism is involved with growth factors secreted by the ASCs under ischemic conditions.
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Figure 13. Conditioned media attenuates necrosis of cardiomyocytes following
ischemia/reoxygenation. (A) In vitro protocol, arrows indicate time points for treatment,
performance of simulated ischemia/reoxygenation, and measurement of various parameters for
each experimental group. (B) Representative image of isolated mouse cardiomyocytes.
Quantitative data showing cell necrosis assessed by trypan blue exclusion assay (C), and LDH
release into the medium (D); (n=4).
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Discussion
Cardiac repair via cellular transplantation has generated considerable enthusiasm in
recent years although the optimal cells for cardiac repair remain to be identified. We chose
adipose-derived stromal/stem cells which have the ability to differentiate into multiple
mesenchymal cell types including endothelial cells (45, 46) and cardiomyocytes (15, 52).
Human ASCs have been shown to preserve heart function following myocardial infarction (133).
In the present study, we investigated the feasibility of PDE-5 inhibition as a strategy to
precondition human ASCs.

The rationale for this approach was the established powerful

preconditioning-like effect of PDE-5 inhibitors in cardiomyocytes (75, 98) and against
ischemia/reperfusion injury in heart (92-94) established by us. Our results show preconditioning
of ASCs by PDE-5 inhibition significantly improved their ability to survive SI/RO injury in
vitro. Moreover, we observed significant release of pro-angiogenic/pro-survival growth factors
including VEGF, b-FGF, and IGF-1. More importantly, we provide the first evidence for robust
expression of PDE-5 in the isolated ASCs.

PDE-5 knockdown with a silencing vector

significantly reproduced the effect of sildenafil in survival against cell death as well as release of
growth factors. These data not only rule out the potential off target effects of sildenafil in ASCs
but also provide us a genetic approach to precondition the stem cells possibly for improving
survival after transplantation. To our knowledge, this is the first study showing PDE-5 as a
target gene/enzyme to improve survival of ASCs under ischemic conditions in vitro. These are
clinically significant observations because improving stem cell survival by exploiting novel
therapeutic targets with clinically approved drugs would directly impact the prognostic outcome
of stem cell therapy in the heart.
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We have shown that sildenafil reduced myocardial infarction in the intact heart and
apoptosis and necrosis in cardiomyocytes subjected to simulated ischemia and reoxygenation
through nitric oxide (NO)-dependent pathway (75).

Sildenafil induced a delayed

cardioprotective effect in the mouse heart that involved the upregulation of iNOS and eNOS
(91). ASCs have been shown to endogenously generate NO which can be measured in biological
systems as metabolites of NO such as nitrite and nitrate (134). Our results indicate a significant
increase in concentrations of nitrate and NOx (nitrate + nitrite) in culture medium following
sildenafil treatment of ASCs as compared to non-treated cells. Interestingly, shRNAPDE-5 ASCs
exhibited a trend towards increased NO generation as compared to control ASCs; however, there
was not a significant difference in NO metabolites as compared the shRNA CON ASCs. The
downstream targets and cellular actions of NO are known to be dependent on its local
concentrations with normal in vivo concentrations of NO ranging from low nanomolar to low
micromolar level. Therefore, even modest increases in NO concentration can result in activation
of the major NO receptor, soluble guanylyl cyclase which in turn elevates intracellular cGMP
(101). Enhanced accumulation of cGMP leads to activation of PKG which has been shown to be
involved in cardioprotective effects against I/R injury (102-104). In the present study, there is no
clear evidence that PKG activation seen in preconditioning of ASCs is a result of increased NO
production, although recently, we demonstrated that direct adenoviral overexpression of PKG Iα
in cardiomyocytes induced both iNOS and eNOS and protected these cells against SI/RO injury.
Similarly in isolated cardiomyocytes (75), sildenafil caused a significant increase in mRNA and
protein expression of iNOS and eNOS. Also, sildenafil-induced protection against necrosis and
apoptosis was abolished in cardiomyocytes derived from iNOS but not from eNOS gene
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knockout mice (91). ASCs have been shown to express all three nitric oxide synthases, iNOS
(135), eNOS (45, 136), and nNOS (137), and endogenous generation of NO has been attenuated
with the iNOS/eNOS inhibitor, L-NAME (134). Therefore, it is plausible that the increase in NO
concentrations following sildenafil treatment might be a result of a similar mechanism involving
iNOS/eNOS up-regulation. However, further studies are needed to delineate the exact source of
NO in our model of ASC preconditioning with sildenafil.
Inhibition of PDE-5 by siRNA has been documented to increase levels of cGMP and
increase the angiogenic phenotype of endothelial cells (98, 130). PDE-5 inhibition and activation
of cGMP has also been shown to increase mobilization and exert pro-survival effects on stem
cells (138, 139). In ours and other previous studies, PDE-5 inhibition lead to accumulation of
cGMP to levels that lead to activation of PKG. Phosphorylation of downstream proteins by PKG
regulates such important physiological functions as relaxation of vascular smooth muscle,
inhibition of platelet aggregation and apoptosis, and induction of VEGF (15, 97). We have
demonstrated previously that sildenafil induced activation of PKG and adenoviral overexpression
of PKG in isolated cardiomyocytes resulted in attenuation from necrosis and apoptosis following
ischemia/reoxygenation (75, 114). The present results demonstrate that preconditioning of ASCs
with PDE-5 inhibition exerted a similar cytoprotective effect through a PKG-dependent pathway
as PKG inhibitor, KT 5823, and short-hairpin RNA knock-down of PKG abolished protection.
There are at least two mechanisms contributing to the resistance of ASCs in which PDE-5
is inhibited against hypoxic/ischemic stress. We have previously shown that sildenafil induces a
cytoprotective effect in cardiomyocytes through NO and cGMP dependent activation of PKG
which results in opening of mitochondrial KATP channels (75, 98, 140).

While the
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comprehensive cytoprotective signaling pathways following PDE-5 inhibition in ASCs remains
to be investigated, it is clear that cGMP (but not cAMP) was elevated and PKG was involved in
protecting ASCs against ischemic injury (Figs. 8, 9, 10). PKG is a serine/threonine protein
kinase that has two isozymes (type I and type II; i.e. PKGI and PKGII). PKGIα is mainly found
in lung, heart, platelets, and cerebellum, whereas PKGIβ is highly expressed in smooth muscles
of uterus, vessels, intestine, and trachea (141). As discussed elsewhere, sildenafil activated PKGdependent signaling cascade that involved phosphorylation of ERK and inhibition of GSK-3β
thus leading to cytoprotection (98). Moreover, gene transfer of PKGIα in cardiomyocytes in the
absence of sildenafil or other pathophysiological stimuli (such as ischemic preconditioning)
resulted in a cytoprotective phenotype that was associated with the phosphorylation of Akt,
ERK, and JNK and increased Bcl-2 expression (114). It is quite likely that a similar cascade of
signaling events leads to survival of ASCs after SI.
Another cytoprotective mechanism of PDE-5 inhibition in ASCs may involve the
paracrine effects by secretion of growth factors with angiogenic potential. The present study
clearly demonstrated the increased secretion of VEGF, b-FGF, and IGF-1 from sildenafil- and
shRNAPDE-5-treated ASCs in response to the ischemic conditions. Moreover, the release of
growth factors was blunted under conditions where PKG signaling was disrupted (Fig. 6)
suggesting a critical role of cGMP-PKG pathway in their secretion. These results are supported
by other studies on downregulation of VEGF expression with the inhibition of the downstream
kinase of PKG, GSK3β (142), which are also activated by sildenafil treatment in cardiomyocytes
and exert protective effect against SI/RO injury (98). ASCs have been shown to secrete VEGF
and HGF which possess both angiogenic and anti-apoptotic effects on both myocardial and
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endothelial cells (47). Furthermore, these paracrine factors from stem cells have been shown to
protect co-cultured adult

cardiomyocytes

against

hypoxic/ischemic

stress (144-146).

Accordingly, we observed that adult mouse cardiomyocytes cultured with conditioned medium
from sildenafil treated ASCs survived better than those cultured with conditioned medium from
non-treated cells. Therefore, transplantation of ASCs preconditioned through PDE-5 inhibition
could provide adequate magnitude and duration of VEGF, b-FGF, and IGF-1 release in the
ischemic myocardium, which would provide cardioprotective effects leading to the salvaging of
ischemic myocardium and decrease the infarcted area.
In summary, this study demonstrates that preconditioning of ASCs through PDE-5
inhibition, improved survival under conditions of ischemia/reoxygenation via PKG activation
and enhanced paracrine action. We propose that in vitro preconditioning of ASCs by inhibition
of PDE-5 with small molecule drugs or gene silencing vectors can be a powerful new approach
to improve stem cell therapy following myocardial infarction in patients. Particularly the easy
availability of ASCs from humans combined with the preconditioning by inhibition of PDE-5
may hold great promise for initiation of clinical trials in heart failure patients.
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CHAPTER 3
Preconditioning by Phosphodiesterase-5 Inhibition Improves Therapeutic Efficacy of
Adipose Derived Stem Cells Following Myocardial Infarction

ABSTRACT
Cell-based therapies for the prevention and treatment of cardiac dysfunction offer the potential to
significantly alter cardiac function and improve the outcome of patients with cardiovascular
disease. To date several clinical studies have suggested the potential efficacy of stem cell
therapy; however, the benefits have been limited and inconsistent. We have demonstrated that
preconditioning of adipose-derived stem cells (ASCs) through PDE-5 inhibition improves their
viability following simulated ischemia and re-oxygenation. We therefore tested the hypothesis
that ex vivo preconditioning of ASCs with sildenafil (Viagra) or selective knockdown with a
silencing vector would enhance cardiac function following myocardial implantation in vivo.
ASCs were preconditioned by treatment with sildenafil or PDE-5 silencing vector shRNA
(shRNAPDE-5). Adult male CD-1 mice underwent myocardial infarction (MI) by occlusion of left
descending coronary artery. Animals received PBS and preconditioned ASCs (4x10 5) by direct
intramyocardial injection into left ventricular wall. Cardiac function and structure were evaluated
by serial echocardiography and histology. Preconditioned ASCs-treated hearts showed
consistently superior cardiac function by all measures as compared with PBS and non-
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preconditioned ASCs 4 weeks after treatment. Post-mortem histological analysis demonstrated
that preconditioned ASCs-treated mice had significantly reduced fibrosis, increased vascular
density and decreased resident myocyte apoptosis as compared to mice that received nonpreconditioned ASCs or PBS. Plasma levels of VEGF, b-FGF, and Ang-1 were also significantly
elevated 4 weeks after cell therapy with preconditioned ASCs. We conclude that ex vivo
inhibition of PDE-5 prior to transplantation can be a potent new approach to improve stem cell
therapy following myocardial infarction.
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Introduction
Over the past several years, experimental findings suggest there is a therapeutic potential
for cellular replacement therapy as treatment of acute myocardial infarction (MI) and other
progressive chronic cardiac diseases such as left ventricular (LV) remodeling and heart failure.
Since cardiovascular disease remains a worldwide problem, the development of novel effective
cell-based therapies is crucial to improve patient outcome post MI. Current therapies strive to
limit both the loss of cardiomyocytes and adverse remodeling in order to preserve cardiac
systolic function; however, treatment of MI still leaves a significant number of patients with
impaired cardiac function that leads to more severe LV dysfunction and adverse remodeling.
Remodeling of the ventricle is a result of increased cardiomyocyte apoptosis in the ischemic
zones after infarction. While apoptosis influences remodeling, the other form of cellular death
that occurs in the heart, necrosis, provokes inflammatory reactions, neoangiogenesis, fibroblast
activation, and scar formation. Therefore, limiting myocardial apoptosis and necrosis is of
critical importance.
Phase II and III clinical studies indicate that stem cell transplantation is feasible and may
have beneficial effects on ventricular remodeling after myocardial infarction. However, to date,
most of the cellular based therapies have shown limited efficacy because the majority of
transplanted cells are readily lost after transplantation due to poor blood supply,
ischemia/reperfusion injury, and inflammatory factors. Disconcerting reports have shown that
up to 99% of transplanted cells are lost within the first 24 hours (73). Therefore, enhancing cell
viability and reduction of apoptosis of ASCs in an ischemic microenvironment of the infarcted
heart is critical for improving the efficiency of cell therapy. In the previous chapter, we have
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demonstrated that in vitro PDE-5 inhibition of ASCs by sildenafil or genetic knock-down with a
silencing vector improved cell viability, attenuated necrosis and apoptosis following simulated
ischemia/reoxygenation (SI/RO) through a PKG-dependent mechanism. Moreover, we
demonstrated the increased secretion of pro-angiogenic/pro-survival growth factors: VEGF; bFGF; and IGF-1 from sildenafil and shRNAPDE-5 -treated ASCs in response to the ischemic
conditions. Transplantation of ASCs along with their secretion of VEGF, bFGF, and IGF-1, and
has been shown to upregulate the anti-apoptotic protein, Bcl-2, which results in the decrease in
cardiomyocyte apoptosis (58). Similarly, we showed that treatment with conditioned medium
from sildenafil-treated ASCs resulted in a cytoprotective effect on cultured adult mouse
myocytes following SI/RO through attenuation of necrosis and apoptosis.
In this study, we tested the hypothesis whether PDE-5 inhibition could improve the
survival and engraftment of ASCs which may lead to enhanced cardiac function following
myocardial infarction in mice.

Specifically we addressed the question: Whether in vivo

transplantation of ASCs after ex vivo PDE-5 inhibition improve LV function following
myocardial infarction. Our results show that ex vivo PDE-5 inhibition of ASCs prior to
myocardial transplantation enhances their therapeutic potential as shown by reduced fibrosis,
cardiomyocyte apoptosis, improved vascular density and cardiac function in mice following
myocardial infarction.
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Materials and Methods
Animals
Adult male outbred CD-1 mice (~30g) were supplied by Harlan Sprague Dawley. Upon their
arrival, the animals were allowed to readjust to the housing environment for at least 3 days
before any experiment. Standard food and water were freely accessible for the animals used in
these studies. The care and use of the animals were conducted in accordance with the guidelines
of the Institutional Animal Care and Use Committee of Virginia Commonwealth University and
the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals
[DHHS Publication No. (NIH) 80-23; Office of Science and Health Reports, Bethesda, MD
20205].

Myocardial Infarction (MI) Protocol
Adult CD-1 mice underwent permanent occlusion of the left descending coronary artery
as previously described (97). In brief, the animals were anesthetized with pentobarbital (70
mg/kg ip), intubated orotracheally and ventilated on a positive-pressure ventilator. The tidal
volume was set at 0.2 ml, and the respiratory rate was adjusted to 133 cycles/min. All surgical
procedures were carried out under sterile conditions. A left thoracotomy was performed at the
fourth intercostal space, and the heart was exposed by stripping the pericardium. The left
descending coronary artery (LAD) was then identified and permanently occluded by a 7.0 silk
ligature that was placed around it. After coronary artery occlusion, the air was expelled from the
chest. The animals were extubated and then received intramuscular doses of analgesia (buprenex;
0.02mg/kg) and antibiotic (Gentamicin; 0.7 mg/kg; for 3 days).
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Transplantation of ASCs
Immediately after ligation, 4x105 ASCs (total of 30µL) were injected at 3 injection sites
into anterior and lateral wall of the LV bordering the infarction. The control group was injected
with identical volume of PBS at similar sites (Fig. 15). To determine the fate of ASCs post
transplantation, the cells were labeled with PKH26 dye using a PKH-26 Cell Linker Kit (Sigma)
according to the supplier’s instructions. The chests were sutured, and animals were allowed to
recover. The hearts were harvested for histological studies 4 weeks post cellular transplantation.
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Group 1- Sham
Group 2- MI + PBS
Group 3- MI+ ASC
Group 4- MI + Sil ASC
Group 5- MI + shRNACON ASC
Group 6- MI + shRNAPDE-5 ASC

8 week-old
CD-1
Male
Mice

28 Days
24 hours adenoviral infection;
sildenafil treatment (10μM for 2
hours)
Start of MI and immediate
injection of 4 x 105 ASCs
labeled with PKH26 at 3
sites bordering infarct

•Echocardiography
•Trichrome
•TUNEL
•Markers of Differentiation
•Vascular Density
•Growth Factor Release

Figure 15. Experimental protocol. In vivo protocol, arrows indicate time points for treatment,
performance of surgical procedures, and measurement of various parameters for each
experimental group. Arrowheads indicate sites of injection of adipose-derived stem cells in the
border zone of the infarcted heart.
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Echocardiography
Doppler Echocardiography was performed using the Vevo770TM imaging system
(VisualSonics Inc., Toronto, Canada) prior to surgery (baseline), and 4 weeks after surgery using
techniques similar to those previously reported (97). Mice were anesthetized with pentobarbital
sodium (30 mg/kg ip). The mice were placed in the supine position. The chest was carefully
shaved, and ultrasound gel was used on the thorax to optimize visibility during the exam. A 30MHz probe was used to obtain two-dimensional (B-Mode), and cross-sectional (M-mode)
imaging from parasternal short-axis view at the level of the papillary muscles. The M-mode
cursor was positioned perpendicular to the anterior and posterior wall to measure left ventricular
(LV) end-diastolic and end-systolic diameters (LVEDD and LVESD, respectively). M-mode
images were then obtained at the level of the papillary muscles below the mitral valve tip. LV
fractional shortening (FS) was calculated as follows: FS=(LVEDD–LVESD)/LVEDDx100.
Ejection fraction was calculated with the Teichholz formula.

Histology
Following the 4 week post-MI echo, the mice were sacrificed and subsequently, the
hearts were excised, trimmed free of the atria, vena cava, and pulmonary vessels, and prepared
for histology. In brief, the aorta was attached to a Langendorff apparatus and the heart was
perfused in retrograde fashion with saline to remove the residual blood. Tranverse sections of the
median third of the LV (n = 4-6/group) were flash frozen in liquid nitrogen and sent to VCU
Tissue and Data Acquisition and Analysis Core (TDAAC) Facility for tissue processing and
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cryosectioning. Apoptosis was examined using TUNEL assay according to manufacturer’s
instructions which were described in Chapter 2. The apoptotic rate was expressed as the number
of apoptotic cells of all cardiomyocytes per field. The apoptotic rate in the peri-infarct regions
was calculated using 10 random fields, which virtually cover the entire peri-infarct area.
Myocardial fibrosis was examined to address prevalence of scar formation within the LV.
Heart sections (5 μm) were stained with Masson’s trichrome (Sigma). Fibrotic area was
computed using computer morphometry (Bioquant) and expressed as a percentage of left
ventricle.

Determination of Vascular Density
The vascular density in the peri-infarct region of myocardial tissue was determined as
previously described (147). In brief, tissue sections were stained using CD-31 antibody
(Millipore) for evaluation of vascular density. Blood vessels were quantified using
histomorphometry. Vessels were distinguished from larger arterioles and venules by deriving
lumen diameters from area assessments of each vessel. Only vessels with diameters <10 μm and
cut in an orthogonal fashion were considered and included in the quantification. For
quantification of positively stained vessels, five sections within the peri-infarcted area of each
animal were analyzed. Blood vessels were detected at low magnification, x 200.
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Data Analysis and Statistics
Data are presented as mean ± S.E. The differences between groups were analyzed with
one way analysis of variance followed by Student-Newman-Keuls post hoc test for pair-wise
comparison. P<0.05 was considered to be statistically significant.
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Results
PDE-5 Inhibition Enhances ASC Survival in Infarcted Hearts
To determine the engraftment of ASCs, we examined myocardial tissue sections for the
presence of PKH26 positive cells. Donor PKH26 positive cells were identified only in mice that
received ASCs after treatment with sildenafil or shRNAPDE-5. PKH26-positive cells were present
primarily within the epicardial layer of the infarct border zone region (Fig. 16). There was no
evidence of engrafted ASCs in mice receiving control non-preconditioned ASCs. To determine
endothelial cell differentiation of ASCs, we immunostained heart sections with endothelial cell
specific marker, CD31, and assessed for co-localization of PKH26 positive cells. Animals
receiving ASCs treated with sildenafil or shRNAPDE-5 showed CD31 positive cells.
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MI + ASC
ASC

MI + Sil ASC

MI + shRNACON ASC

MI + shRNAPDE-5 ASC

MI + ASC

MI + Sil ASC

MI + shRNACON ASC

MI + shRNAPDE-5 ASC

B.

Figure 16. Tracking of PKH26 labeled ASCs following myocardial infarction. ASCs were
preconditioned with sildenafil (Sil) or shRNAPDE-5 and injected in the LV wall following
myocardial infarction. (A) PKH26 labeled ASCs Labeled (red) transplanted Sil or shRNA PDE-5
ASCs. DAPI (blue) was used to visualize nuclei. (B) Immunostaining of CD31 (green), PKH26
(red) and DAPI (blue).
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Preconditioned ASCs Improve Cardiac Function, Reduce Fibrosis and Apoptosis
Figure 17A shows representative M-mode images 4 weeks after MI. Significant
functional loss continued over the following 28 days in saline-treated hearts. Echocardiography
recordings show that values for all measures of LV function decreased significantly in hearts
treated with PBS post MI as compared with sham. Conversely, hearts injected with ASCs
demonstrated a trend toward an increase in function. However, treatment with preconditioned
ASCs demonstrated significant improvement in function as compared with non-preconditioned
cells or PBS. Specifically, LVEDD, LVESD, EF, and FS were improved significantly in mice
receiving sildenafil-treated ASCs as compared with mice receiving non-treated ASCs at 4 weeks
after MI (Fig. 17). Administration of ASCs preconditioned with shRNAPDE-5 also caused similar
enhanced preservation of cardiac function and attenuation of cardiac remodeling as compared to
ASCs treated with control vector. There were no significant differences in the echo parameters
in mice receiving shRNACON ASCs and non-treated ASCs (Fig. 17).
The percentage of fibrosis in the LV wall was 55 to 60% lower in hearts receiving ASCs
preconditioned with PDE-5 inhibition as compared to non-treated ASCs (7.1±0.7% with
sildenafil-treated ASCs; 6.8±1.7% with shRNAPDE-5 ASCs vs

14.9±3.8% with non-treated

ASCs, p < .05, n=5). All cellular treatment groups showed significant reduction in fibrosis
compared with PBS controls (31.3±3.8%, Fig. 18). Also, the reduction in fibrosis seen in
sildenafil-treated and shRNAPDE-5 ASCs correlated with a reduction of cardiomyocyte apoptosis.
PBS-treated mice after 4 weeks of permanent occlusion had a resident myocyte apoptotic rate of
3.3±0.32%, which was reduced to 1.9±0.23% in non-treated ASC group. Sildenafil-treated or
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shRNAPDE-5 ASCs injected mice further reduced apoptosis (0.9±.14% with sildenafil and
0.8±.12% with shRNAPDE-5 ASCs, p<0.05 vs. PBS control, n=5, Fig. 19).
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Figure 17. Transplantation of preconditioned ASCs improves cardiac function and
remodeling following myocardial infarction. (A) Representative M-mode images showing
preservation of LV contractility of hearts treated with preconditioned ASCs as compared with
non-treated ASCs control following myocardial infarction (MI). Bar diagram showing
quantitative data of hearts treated with preconditioned ASCs as compared with non-treated ASCs
control following myocardial infarction. (B) LV end-diastolic diameter; (C) end-systolic
diameter; (D) fractional shortening; (E) ejection fraction; (n≥5).
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Figure 18. Preconditioned ASCs reduces myocardial fibrosis following myocardial
infarction. (A) Representative Masson’s trichrome staining of tissue sections and accompanying
(B) bar diagram showing quantification of the amount of fibrosis (n=4).
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Figure 19. Preconditioned ASCs reduces myocardial apoptosis following myocardial
infarction. (A) Representative TUNEL staining of sections and (B) bar diagram showing
quatification of TUNEL positive cells; (n=4).
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Preconditioned ASCs Increase Vascular Density and Secretion of Growth Factors
Rapid restoration of blood supply to the ischemic region is critical for stabilizing the
border region of the infarct and supporting viable and regenerating myocardium. We used CD31 positive staining to determine the vascular density in the border zone of MI. Transplantation
of ASCs significantly increased vascular density as compared with that of PBS-treated hearts
(Fig. 20). However, the vascular density in sildenafil and shRNAPDE-5 ASCs treated mice was
significantly enhanced as compared to non-treated ASCs mice (8.3±1.3 in sildenafil-treated
ASCs; 7.8±0.5 shRNAPDE-5 ASCs vs 4.5±0.6 vessels/HPF, p<0.01, n=4) (Fig. 20). Moreover, the
plasma levels of b-FGF, Ang-1, and VEGF were significantly increased in mice receiving
preconditioned ASCs (with sildenafil-treated or shRNAPDE-5 ASCs) as compared to non-treated
ASCs (p<0.001, n=5, Fig. 21).
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Discussion
Current treatment of MI still leaves a significant number of patients with impaired
cardiac function that leads to more severe LV dysfunction as the ventricle remodels. Thus, cell
therapy has generated much excitement as a novel therapy that might provide additive benefits
over conventional treatment to restore or prevent further LV dysfunction after MI. Although
there have been several reports that ASCs improve cardiac function post-MI effects have been
limited (69-72). This study investigated the feasibility of ex vivo preconditioning by PDE-5
inhibition as a strategy to enhance the efficacy of stem cell therapy post-MI. As described in
Chapter 2, PDE-5 inhibition in ASCs confers a powerful preconditioning-like effect against
SI/RO limiting apoptosis and necrosis thus increasing survivability. The present study shows
significant improvement in cardiac function 4 weeks after transplantation of preconditioned
ASCs as demonstrated by significant preservation of FS and EF as compared to other treatment
groups. Moreover, the superior functional improvement compared with non-preconditioned
ASC injected group was associated with enhanced vascular density (Fig. 20), decrease in fibrosis
and resident cardiomyocyte apoptosis (Fig. 18, 19). The observed benefits correlated with
increased plasma levels of pro-angiogenic growth factors including VEGF, b-FGF, and Ang-1.
Various studies have reported the beneficial effects of stem cell therapy without longterm engraftment, and a link between donor cell-derived factors and LV recovery following
cellular transplantation (67, 148-150). In the present study, we also observed a very limited
number of PKH26 positive ASCs cells that were identified only in hearts which received
preconditioned ASCs.

PKH26-positive cells were present primarily in the epicardium of the

border zone regions after 4 weeks (Fig. 16). The observation that only a limited number of
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preconditioned cells were present 4 weeks post-MI is consistent with other studies that suggest
that improving the effectiveness of graft patency with stem cells is dependent on increased
concentrations of NO (151). We observed an increase in NO generation following sildenafil
treatment (Chapter 2). Furthermore, other studies have showed a rapid loss of transplanted cells
after 24 h and 7 d following direct intramyocardial injection post-MI. Moreover similar to our
study, it was reported that the numbers of cells present in the post-MI heart were almost
negligible by 2 weeks. However, cellular transplantation still attenuated LV dysfunction and
remodeling, reduced myocyte apoptosis and augmented myocardial neovascularization, despite
poor engraftment of transplanted cells (152).

Another study by MacLellan et al (51)

demonstrated the ability of ASCs, delivered acutely following LAD ischemia/reperfusion, to
improve cardiac function independent of engraftment. This is in agreement with Limbourg et al.
who also showed that hematopoietic stem cells can improve cardiac function post-MI, even in
the absence of sustained engraftment (153). Interestingly, similar reductions in fibrotic tissue
have been observed when either the supernatant from the modified cells or specific secreted
proteins used to modify the mesenchymal stem cell were injected into the infarct zone (66).
These observations support the paracrine hypothesis of myocardial repair, and suggest not only
the potential for pharmacological or genetic enhancement of stem cell therapies, but also suggest
that high degree of benefit observed with cell therapy is independent of cellular engraftment. As
cellular differentiation does not appear to play a major role in the therapeutic effect of ASCs in
this model system, it is logical to hypothesize that the paracrine release of cytokines and growth
factors by the transplanted ASCs in the first few days or weeks after injection is responsible for
the observed effects. Consistent with our results, it is possible that a small number of specifically
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conditioned or genetically altered cells may be able to exploit paracrine pathways to maximize
the biological and clinical effects after cell delivery (9, 58 148, 154-159). Paracrine factors
released by modified or preconditioned ASCs potentially mediate multiple mechanisms such as
myocardial cell survival, remodeling, contractility, increased blood flow to ischemic tissue,
regulation of inflammatory response, and recruiting endogenous stem cells to regenerate injured
tissue. The lack of significant engraftment despite tremendous reduction in cardiac fibrosis seen
in the preconditioned ASC treatments suggests that a paracrine mechanism from enhanced
secretion of growth factors may play an important beneficial role in repairing the damaged
myocardium.
This proposed mechanism has been suggested by other investigators examining stem cell
therapy administered acutely post-MI. Angiogenic and cytoprotective growth factors such as
VEGF and Ang-1 have been shown to significantly improve cardiac function through increased
angiogenesis and decreases in infarct size when administered acutely or delivered as a gene
construct post-MI (21, 57, 59). Similarly, Li et al. showed that increased capillary density
following ASC treatment in a rat model of MI that correlated with higher VEGF mRNA and
protein levels (57). Experiments have compared the effects of individual angiogenic genes, Ang1 and VEGF with ASC therapy in a murine model of MI. While both Ang-1 and VEGF
significantly improved cardiac performance, ASCs were superior in alleviating diastolic function
and improving capillary density. In our present study, we observed that reduction in fibrosis
following transplantation of preconditioned ASC was associated with increased angiogenesis in
the infarcted areas in post-MI hearts as demonstrated by increased capillary and arteriole density
within the infarct border zones (Fig. 20). Our results showed that the observed improved vascular
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density after transplantation of preconditioned ASCs was correlated with increased secretion of
growth factors with angiogenic potential; b-FGF, IGF-1 and VEGF (Chapter 2).

While

myocardial hypoxia during infarction has been demonstrated to induce expression of angiogenic
growth factors including VEGF, the increased plasma levels of VEGF, Ang-1, and b-FGF we
observed following treatment with preconditioned ASCs suggests the increased duration of
ASCs within the ischemic microenvironment possibly allows them to function as ―paracrine
pumps‖ to sustain increased levels of growth factors which are known to lead to increased
angiogenesis, suppression of cardiac fibrosis, and attenuation of cardiomyocyte apoptosis.
A number of studies have shown that apoptosis in cardiomyocytes contributes to the
progression of heart failure after MI (97, 160), and chronic cardiac remodeling with chamber
dilation and impaired systolic function is associated with increased myocyte apoptosis in the
infarct border zone after MI (161). Our results demonstrate that transplantation of preconditioned
ASCs abrogated resident cardiomyocyte apoptosis seen in non-treated ischemic hearts.
Furthermore, the extent of apoptosis was significantly lower from preconditioned ASC treated
hearts compared with control ASC treated hearts at 28 days post-MI. Overexpression of Ang-1,
VEGF, or b-FGF has been shown to improve cell survival, neovascularization, and cardiac
function by limiting the remodeling process in the scar while decreasing apoptosis of myocytes
in the peri-infarct region (21, 58, 78). Transplantation of ASCs along with their secretion of
VEGF, bFGF, and IGF attenuated cardiomyocyte apoptosis in vitro and in vivo (21).
Preconditioning of ASCs through PDE-5 inhibition exerts a similar cardioprotective effect. The
present results are consistent with the limitation of necrosis and apoptosis of adult
cardiomyocytes treated with conditioned medium and preconditioned ASCs subjected to SI/RO
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(Chapter 2) suggesting that the protective effect is attributed to increased duration and release of
paracrine factors in the ischemic myocardium.
Besides the increased duration of pro-survival growth factors, another explanation for the
cardioprotection seen following transplantation of preconditioned ASCs, could be due to the
induction of NO generation following PDE-5 inhibition observed in Chapter 2. We speculate that
increased duration of preconditioned ASCs concomitant with increased NO release could allow
for diffusion of NO into the ischemic region and possibly preserve cardiomyocytes through the
opening of mitoKATP channels, preventing Ca2+ overload, and reducing oxidative stress.
Moreover, we have shown that sildenafil attenuated apoptosis as well as necrosis in
cardiomyocytes subjected to simulated ischemia and reoxygenation through nitric oxide (NO)dependent pathway (75). It is also likely that the reduction of fibrotic tissue seen after cellular
treatment with preconditioned ASCs could be the result of increased generation of NO that could
then diffuse into the ischemic zone and restore the cGMP/PKG pathway. We have reported
previously that sildenafil-induced increases in NO is involved in infarct size reduction after 24 h,
even in a model of permanent LAD occlusion as the infarct sparing effect of sildenafil were
blocked with NOS inhibitor, L-NAME (91). Although, there is no clear mechanism for the
observed reduction of apoptosis and fibrosis following preconditioned ASC therapy, it is likely
that increased release of NO along with pro-survival growth factors confers a cardioprotective
mechanism through enhanced paracrine signaling.

However, further studies are needed to

investigate the role of NO in our model.
In conclusion, we have shown that ex vivo preconditioning of ASCs by PDE-5 inhibition
prior to transplantation into mice post-MI ameliorates LV remodeling, preserves LV function,
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and reduced cardiomyocyte apoptosis and fibrosis possibly by improving stem cell survival and
paracrine effects. Sildenafil is already being tested clinically in patients with heart failure and
preserved ejection fraction (i.e. EF>50%) in the ongoing NIH multicenter trial (RELAX:
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise
Ability in People With Diastolic Heart Failure; NCT00763867). We believe that the easy
availability of ASCs from humans during surgery combined with the preconditioning strategy of
blocking PDE-5 using clinically approved PDE-5 inhibitors may hold great promise for initiation
of clinical trials in heart failure patients.

Funding Sources: This study was supported by grants from National Institutes of Health
(HL51045, HL79424 and HL93685) to Rakesh C. Kukreja, National Scientist Development
Grant from the American Heart Association (10SDG3770011) to Fadi N. Salloum, and
Predoctoral Fellowship from the American Heart Association (09PRE2250905) to Nicholas N.
Hoke.

Chapter 4
Conclusion and Future Directions

Ischemic heart disease (IHD) remains a leading cause of morbidity and mortality despite
recent advances in pharmacotherapy and improved acute care. Increased incidence of risk factors
such as hypertension, obesity, diabetes, and smoking over the last several decades have all
contributed to this increased prevalence of IHD. Therefore a conceptual breakthrough is needed
to develop novel targets and strategies to prevent and cure IHD.

In recent years, cardiac repair

by stem cells has gained tremendous attention and imagination because of its initial success and
safety potential. However, there are several major hurdles such as improvement in the number of
reparative cells homing to injured areas, selection of ideal cell type(s), enhancement of
regenerative and differentiation capacity of transplanted cells and optimization of extracellular
milieu for engraftment and differentiation that would significantly impact long-term beneficial
effects on cardiac functions. In the present study, we have used an innovative strategy of
preconditioning the adipose stem cells (ASC) through inhibition of phosphodiesterase-5 (PDE-5)
by sildenafil or genetic knockdown with a silencing vector.

Our results showed that

preconditioned ASC developed significant resistance against ischemic injury in vitro with both
of these approaches.

Furthermore, transplantation of preconditioned ASC following a chronic
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model of myocardial infarction (MI) resulted in amelioration of left ventricular (LV) remodeling,
preserved LV function, reduced cardiomyocyte apoptosis and fibrosis possibly by improving
stem cell survival through paracrine effects. We also like to mention that sildenafil is an
interesting drug because it is widely used for treatment of erectile dysfunction and other
cardiovascular disorders including pulmonary hypertension in patients. Moreover, there is an
ongoing NIH multicenter trial (RELAX: Evaluating the Effectiveness of Sildenafil at Improving
Health Outcomes and Exercise Ability in People With Diastolic Heart Failure; NCT00763867) in
patients with heart failure. Another clinical trial on sildenafil has recently been initiated
(REVERSE-DMD, NCT01168908) to treat Duchenne’s patients with cardiac disease, which is
currently recruiting patients at the Johns Hopkins Medical Institutions. Because of the clinical
safety and efficacy of sildenafil, we believe that this drug would be an ideal candidate to trigger
cGMP-dependent surivival pathway for preconditioning of ASC and their eventual use in
patients for myocardial repair
We also like to stress that despite our promising results, further studies need to be done to
investigate the role of PDE-5 inhibition in enhancing stem cell therapy. In particular the effect
of preconditioned ASC transplantation should be examined in a model of ischemia/reperfusion
injury model in addition to the permanent ischemia model used in the current investigation. This
is because the majority of patients with acute myocardial infarction undergo spontaneous or
therapeutic reperfusion.

Reperfusion is known to cause tissue damage when blood supply

returns to the tissue following ischemia. The restoration of circulation following the absence of
oxygen and nutrients from blood results in a surge of free radicals in the form of reactive oxygen
species and oxidative stress causing subsequent oxidative damage and inflammation.
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Consequently, it is of utmost importance to determine whether ASC are effective when coronary
occlusion is followed by reperfusion, an event that dramatically alters the milieu of the
myocardial interstitium and of the myocardium itself.
In addition to the physiological studies, there is critical need to examine new molecular
mechanisms by which preconditioning of ASC leads to improvement in cardiac function and
preservation of myocardial structure.

We will study the role of PKG in mediating the

cytoprotective effect by using strategies such as overexpression of PKG-1α in ASC using
adenoviral/lentiviral approaches prior to transplantation in the heart. We also plan to study the
role frizzled related protein 2 (Sfrp2) as a survival molecule in ASCs preconditioned with PDE-5
inhibition/PKG1α overexpression.

Recent studies have identified sfrp2 as a key survival

molecule which acts via the canonical Wnt/β-catenin pathway (162). We anticipate that our
current study and future efforts would lead to expanding the use of sildenafil and other clinically
used PDE-5 inhibitors in regenerative medicine.
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